US8399643B2
(en)
|
2009-02-26 |
2013-03-19 |
Transposagen Biopharmaceuticals, Inc. |
Nucleic acids encoding hyperactive PiggyBac transposases
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP3871498A1
(en)
|
2009-07-08 |
2021-09-01 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9585920B2
(en)
|
2011-02-04 |
2017-03-07 |
Katherine Rose Kovarik |
Method and system for treating cancer cachexia
|
US9457077B2
(en)
|
2009-11-18 |
2016-10-04 |
Katherine Rose Kovarik |
Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
|
US11951140B2
(en)
|
2011-02-04 |
2024-04-09 |
Seed Health, Inc. |
Modulation of an individual's gut microbiome to address osteoporosis and bone disease
|
US11419903B2
(en)
|
2015-11-30 |
2022-08-23 |
Seed Health, Inc. |
Method and system for reducing the likelihood of osteoporosis
|
US10085938B2
(en)
|
2011-02-04 |
2018-10-02 |
Joseph E. Kovarik |
Method and system for preventing sore throat in humans
|
US10548761B2
(en)
|
2011-02-04 |
2020-02-04 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of colorectal cancer in a human being
|
US11191665B2
(en)
|
2011-02-04 |
2021-12-07 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
|
US11273187B2
(en)
|
2015-11-30 |
2022-03-15 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing depression in an individual
|
US9730967B2
(en)
|
2011-02-04 |
2017-08-15 |
Katherine Rose Kovarik |
Method and system for treating cancer cachexia
|
US10111913B2
(en)
|
2011-02-04 |
2018-10-30 |
Joseph E. Kovarik |
Method of reducing the likelihood of skin cancer in an individual human being
|
US10842834B2
(en)
|
2016-01-06 |
2020-11-24 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
|
US10583033B2
(en)
|
2011-02-04 |
2020-03-10 |
Katherine Rose Kovarik |
Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
|
US10245288B2
(en)
|
2011-02-04 |
2019-04-02 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
|
US11523934B2
(en)
|
2011-02-04 |
2022-12-13 |
Seed Health, Inc. |
Method and system to facilitate the growth of desired bacteria in a human's mouth
|
US9987224B2
(en)
|
2011-02-04 |
2018-06-05 |
Joseph E. Kovarik |
Method and system for preventing migraine headaches, cluster headaches and dizziness
|
US10086018B2
(en)
|
2011-02-04 |
2018-10-02 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of colorectal cancer in a human being
|
US11844720B2
(en)
|
2011-02-04 |
2023-12-19 |
Seed Health, Inc. |
Method and system to reduce the likelihood of dental caries and halitosis
|
US11357722B2
(en)
|
2011-02-04 |
2022-06-14 |
Seed Health, Inc. |
Method and system for preventing sore throat in humans
|
US10940169B2
(en)
|
2015-11-30 |
2021-03-09 |
Joseph E. Kovarik |
Method for reducing the likelihood of developing cancer in an individual human being
|
US10687975B2
(en)
|
2011-02-04 |
2020-06-23 |
Joseph E. Kovarik |
Method and system to facilitate the growth of desired bacteria in a human's mouth
|
US11951139B2
(en)
|
2015-11-30 |
2024-04-09 |
Seed Health, Inc. |
Method and system for reducing the likelihood of osteoporosis
|
US10512661B2
(en)
|
2011-02-04 |
2019-12-24 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
|
US10010568B2
(en)
|
2011-02-04 |
2018-07-03 |
Katherine Rose Kovarik |
Method and system for reducing the likelihood of a spirochetes infection in a human being
|
US10314865B2
(en)
|
2011-02-04 |
2019-06-11 |
Katherine Rose Kovarik |
Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
|
US10835560B2
(en)
|
2013-12-20 |
2020-11-17 |
Joseph E. Kovarik |
Reducing the likelihood of skin cancer in an individual human being
|
EA202191537A1
(ru)
|
2011-06-30 |
2022-01-31 |
Эрроухэд Фармасьютикалс, Инк. |
Композиции и способы ингибирования экспрессии генов вируса гепатита в
|
CA2853829C
(en)
|
2011-07-22 |
2023-09-26 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
JP5813880B2
(ja)
|
2011-09-19 |
2015-11-17 |
カイマブ・リミテッド |
ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
US10465042B2
(en)
|
2011-12-02 |
2019-11-05 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
CN104080462B
(zh)
|
2011-12-16 |
2019-08-09 |
塔尔盖特基因生物技术有限公司 |
用于修饰预定的靶核酸序列的组合物和方法
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US9637739B2
(en)
*
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
IN2014DN09261A
(lt)
|
2012-04-25 |
2015-07-10 |
Regeneron Pharma |
|
PE20190844A1
(es)
|
2012-05-25 |
2019-06-17 |
Emmanuelle Charpentier |
Modulacion de transcripcion con arn de direccion a adn generico
|
US10564147B2
(en)
|
2012-05-25 |
2020-02-18 |
The Regents Of The University Of California |
Microfluidic systems for particle trapping and separation using cavity acoustic transducers
|
EP2858486A4
(en)
*
|
2012-06-12 |
2016-04-13 |
Hoffmann La Roche |
METHODS AND COMPOSITIONS FOR GENERATING ALLLETS WITH CONDITIONAL INACTIVATION
|
US20150225734A1
(en)
|
2012-06-19 |
2015-08-13 |
Regents Of The University Of Minnesota |
Gene targeting in plants using dna viruses
|
JP2015527889A
(ja)
*
|
2012-07-25 |
2015-09-24 |
ザ ブロード インスティテュート, インコーポレイテッド |
誘導可能なdna結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
|
KR101656237B1
(ko)
*
|
2012-10-23 |
2016-09-12 |
주식회사 툴젠 |
표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
|
KR102389278B1
(ko)
*
|
2012-10-23 |
2022-04-26 |
주식회사 툴젠 |
표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
|
JP6502259B2
(ja)
|
2012-11-16 |
2019-04-17 |
トランスポサジェン バイオファーマシューティカルズ, インコーポレイテッド |
部位特異的酵素および使用方法
|
SG10202110062SA
(en)
|
2012-11-27 |
2021-11-29 |
Childrens Medical Center |
Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction
|
SG10202107423UA
(en)
*
|
2012-12-06 |
2021-08-30 |
Sigma Aldrich Co Llc |
Crispr-based genome modification and regulation
|
US20140242664A1
(en)
|
2012-12-12 |
2014-08-28 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
ES2701749T3
(es)
|
2012-12-12 |
2019-02-25 |
Broad Inst Inc |
Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
|
SG10201801969TA
(en)
|
2012-12-12 |
2018-04-27 |
Broad Inst Inc |
Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
|
ES2883590T3
(es)
*
|
2012-12-12 |
2021-12-09 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
|
US8993233B2
(en)
|
2012-12-12 |
2015-03-31 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
EP2848690B1
(en)
|
2012-12-12 |
2020-08-19 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
EP3252160B1
(en)
*
|
2012-12-12 |
2020-10-28 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
US8697359B1
(en)
*
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
EP2931899A1
(en)
*
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
SG11201504621RA
(en)
*
|
2012-12-17 |
2015-07-30 |
Harvard College |
Rna-guided human genome engineering
|
AU2014207618A1
(en)
*
|
2013-01-16 |
2015-08-06 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
US11135273B2
(en)
|
2013-02-07 |
2021-10-05 |
The Rockefeller University |
Sequence specific antimicrobials
|
WO2014124226A1
(en)
|
2013-02-07 |
2014-08-14 |
The Rockefeller University |
Sequence specific antimicrobials
|
CN103981147B
(zh)
|
2013-02-08 |
2017-11-10 |
中国科学院上海生命科学研究院 |
一种新的制备肝实质细胞的方法
|
JP5954808B2
(ja)
*
|
2013-02-14 |
2016-07-20 |
国立大学法人大阪大学 |
内在性dna配列特異的結合分子を用いる特定ゲノム領域の単離方法
|
EP2958990B1
(en)
|
2013-02-20 |
2019-10-16 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
WO2014131833A1
(en)
|
2013-02-27 |
2014-09-04 |
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Gene editing in the oocyte by cas9 nucleases
|
EP2971184B1
(en)
|
2013-03-12 |
2019-04-17 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
NZ712727A
(en)
|
2013-03-14 |
2017-05-26 |
Caribou Biosciences Inc |
Compositions and methods of nucleic acid-targeting nucleic acids
|
BR112015022522B1
(pt)
*
|
2013-03-15 |
2023-09-26 |
Regents Of The University Of Minnesota |
Método para a modificação do material genômico em uma célula vegetal e vetor viral
|
JP6980380B2
(ja)
*
|
2013-03-15 |
2021-12-15 |
ザ ジェネラル ホスピタル コーポレイション |
短縮ガイドRNA(tru−gRNA)を用いたRNA誘導型ゲノム編集の特異性の増大
|
US20140273230A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
US20140349400A1
(en)
*
|
2013-03-15 |
2014-11-27 |
Massachusetts Institute Of Technology |
Programmable Modification of DNA
|
US9957515B2
(en)
|
2013-03-15 |
2018-05-01 |
Cibus Us Llc |
Methods and compositions for targeted gene modification
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
UA121099C2
(uk)
|
2013-03-15 |
2020-04-10 |
Сібас Юс Ллс |
Спосіб підвищення ефективності спрямованої модифікації генів із застосуванням опосередкованої олігонуклеотидами репарації генів
|
ES2921207T3
(es)
*
|
2013-03-15 |
2022-08-19 |
Cibus Us Llc |
Procedimientos y composiciones para aumentar la eficiencia de la modificación genética direccionada utilizando la reparación genética mediada por oligonucleótidos
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
PT3456831T
(pt)
|
2013-04-16 |
2021-09-10 |
Regeneron Pharma |
Modificação alvejada do genoma de rato
|
US20160186208A1
(en)
*
|
2013-04-16 |
2016-06-30 |
Whitehead Institute For Biomedical Research |
Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
AU2014262867B2
(en)
|
2013-05-10 |
2019-12-05 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
WO2014186435A2
(en)
|
2013-05-14 |
2014-11-20 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for reducing neointima formation
|
EP3730615A3
(en)
|
2013-05-15 |
2020-12-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
WO2014186686A2
(en)
*
|
2013-05-17 |
2014-11-20 |
Two Blades Foundation |
Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
|
US9873907B2
(en)
|
2013-05-29 |
2018-01-23 |
Agilent Technologies, Inc. |
Method for fragmenting genomic DNA using CAS9
|
EP3004339B1
(en)
*
|
2013-05-29 |
2021-07-07 |
Cellectis |
New compact scaffold of cas9 in the type ii crispr system
|
EP3004349B1
(en)
*
|
2013-05-29 |
2018-03-28 |
Cellectis S.A. |
A method for producing precise dna cleavage using cas9 nickase activity
|
US9267135B2
(en)
*
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
MY197877A
(en)
*
|
2013-06-04 |
2023-07-22 |
Harvard College |
Rna-guided transcriptional regulation
|
US9982277B2
(en)
|
2013-06-11 |
2018-05-29 |
The Regents Of The University Of California |
Methods and compositions for target DNA modification
|
EP3008186B1
(en)
|
2013-06-14 |
2018-11-28 |
Cellectis |
Methods for non-transgenic genome editing in plants
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
CA2915837A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
EP3011034B1
(en)
*
|
2013-06-17 |
2019-08-07 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
DK3011029T3
(da)
*
|
2013-06-17 |
2020-03-16 |
Broad Inst Inc |
Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering
|
BR112015031608A2
(pt)
|
2013-06-17 |
2017-08-22 |
Massachusetts Inst Technology |
Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos
|
EP3011032B1
(en)
*
|
2013-06-17 |
2019-10-16 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
CA2917638A1
(en)
|
2013-07-09 |
2015-01-15 |
President And Fellows Of Harvard College |
Multiplex rna-guided genome engineering
|
CN110819658B
(zh)
*
|
2013-07-10 |
2024-03-22 |
哈佛大学校长及研究员协会 |
用于RNA向导的基因调节和编辑的正交Cas9蛋白
|
US9663782B2
(en)
*
|
2013-07-19 |
2017-05-30 |
Larix Bioscience Llc |
Methods and compositions for producing double allele knock outs
|
US10563225B2
(en)
|
2013-07-26 |
2020-02-18 |
President And Fellows Of Harvard College |
Genome engineering
|
US10421957B2
(en)
|
2013-07-29 |
2019-09-24 |
Agilent Technologies, Inc. |
DNA assembly using an RNA-programmable nickase
|
WO2015017866A1
(en)
|
2013-08-02 |
2015-02-05 |
Enevolv, Inc. |
Processes and host cells for genome, pathway, and biomolecular engineering
|
US20150044772A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
Crispr/cas system-based novel fusion protein and its applications in genome editing
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
BR112016003561B8
(pt)
|
2013-08-22 |
2022-11-01 |
Du Pont |
Método para a produção de uma modificação genética, método para a introdução de um polinucleotídeo de interesse no genoma de uma planta, método para a edição de um segundo gene em um genoma de planta e método para gerar uma planta de milho resistente ao glifosato
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
DK3041498T3
(da)
|
2013-09-05 |
2022-05-09 |
Massachusetts Inst Technology |
Afstemning af mikrobielle populationer med programmerbare nukleaser
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9228207B2
(en)
*
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
MX2016003182A
(es)
|
2013-09-11 |
2017-03-31 |
Arsia Therapeutics Inc |
Formulaciones de proteínas líquidas que contienen líquidos iónicos.
|
CN105637087A
(zh)
*
|
2013-09-18 |
2016-06-01 |
科马布有限公司 |
方法、细胞与生物体
|
WO2015049517A2
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
WO2015066119A1
(en)
|
2013-10-30 |
2015-05-07 |
North Carolina State University |
Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
|
EP3862434A1
(en)
*
|
2013-11-04 |
2021-08-11 |
Dow AgroSciences LLC |
Optimal soybean loci
|
WO2015069682A2
(en)
*
|
2013-11-05 |
2015-05-14 |
President And Fellows Of Harvard College |
Precise microbiota engineering at the cellular level
|
WO2015070062A1
(en)
*
|
2013-11-07 |
2015-05-14 |
Massachusetts Institute Of Technology |
Cell-based genomic recorded accumulative memory
|
EP3066201B1
(en)
|
2013-11-07 |
2018-03-07 |
Editas Medicine, Inc. |
Crispr-related methods and compositions with governing grnas
|
CA2930877A1
(en)
*
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
US9546384B2
(en)
|
2013-12-11 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a mouse genome
|
EP3080279B1
(en)
|
2013-12-11 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
KR20160097327A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유전자 산물, 구조 정보 및 유도성 모듈형 cas 효소의 발현의 변경을 위한 crispr-cas 시스템 및 방법
|
EP3835419A1
(en)
*
|
2013-12-12 |
2021-06-16 |
The Regents of The University of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
CN105899658B
(zh)
*
|
2013-12-12 |
2020-02-18 |
布罗德研究所有限公司 |
针对hbv和病毒性疾病以及障碍的crispr-cas***和组合物的递送、用途和治疗应用
|
EP3653229A1
(en)
|
2013-12-12 |
2020-05-20 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
US11053481B2
(en)
*
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
BR112016013213A2
(pt)
*
|
2013-12-12 |
2017-12-05 |
Massachusetts Inst Technology |
administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas
|
CA2932472A1
(en)
*
|
2013-12-12 |
2015-06-18 |
Massachusetts Institute Of Technology |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
WO2015086795A1
(en)
*
|
2013-12-13 |
2015-06-18 |
Cellectis |
Cas9 nuclease platform for microalgae genome engineering
|
EP3080611B1
(en)
|
2013-12-13 |
2018-11-14 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
US20150191744A1
(en)
*
|
2013-12-17 |
2015-07-09 |
University Of Massachusetts |
Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
|
EP3083964B1
(en)
|
2013-12-19 |
2022-01-26 |
Novartis AG |
Human mesothelin chimeric antigen receptors and uses thereof
|
JP6652489B2
(ja)
|
2013-12-19 |
2020-02-26 |
アミリス, インコーポレイテッド |
ゲノム組込みのための方法
|
US11642382B2
(en)
|
2013-12-20 |
2023-05-09 |
Seed Health, Inc. |
Method for treating an individual suffering from bladder cancer
|
US11026982B2
(en)
|
2015-11-30 |
2021-06-08 |
Joseph E. Kovarik |
Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
|
EP3087101A4
(en)
|
2013-12-20 |
2017-12-06 |
Novartis AG |
Regulatable chimeric antigen receptor
|
US11529379B2
(en)
|
2013-12-20 |
2022-12-20 |
Seed Health, Inc. |
Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
|
US11833177B2
(en)
|
2013-12-20 |
2023-12-05 |
Seed Health, Inc. |
Probiotic to enhance an individual's skin microbiome
|
US11213552B2
(en)
|
2015-11-30 |
2022-01-04 |
Joseph E. Kovarik |
Method for treating an individual suffering from a chronic infectious disease and cancer
|
US11672835B2
(en)
|
2013-12-20 |
2023-06-13 |
Seed Health, Inc. |
Method for treating individuals having cancer and who are receiving cancer immunotherapy
|
US11839632B2
(en)
|
2013-12-20 |
2023-12-12 |
Seed Health, Inc. |
Topical application of CRISPR-modified bacteria to treat acne vulgaris
|
US11826388B2
(en)
|
2013-12-20 |
2023-11-28 |
Seed Health, Inc. |
Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
|
EP3985124A1
(en)
*
|
2013-12-26 |
2022-04-20 |
The General Hospital Corporation |
Multiplex guide rnas
|
WO2015103153A1
(en)
*
|
2013-12-31 |
2015-07-09 |
The Regents Of The University Of California |
Cas9 crystals and methods of use thereof
|
SG10201805815YA
(en)
*
|
2014-01-08 |
2018-08-30 |
Harvard College |
Rna-guided gene drives
|
WO2015108993A1
(en)
|
2014-01-14 |
2015-07-23 |
Lam Therapeutics, Inc. |
Mutagenesis methods
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
JP2017503514A
(ja)
*
|
2014-01-24 |
2017-02-02 |
ノースカロライナ ステート ユニバーシティーNorth Carolina State University |
Cas9ターゲッティングをガイドする配列に関する方法および組成物
|
US10354746B2
(en)
*
|
2014-01-27 |
2019-07-16 |
Georgia Tech Research Corporation |
Methods and systems for identifying CRISPR/Cas off-target sites
|
US11315659B2
(en)
*
|
2014-01-27 |
2022-04-26 |
Georgia Tech Research Corporation |
Methods and systems for identifying nucleotide-guided nuclease off-target sites
|
US9850525B2
(en)
*
|
2014-01-29 |
2017-12-26 |
Agilent Technologies, Inc. |
CAS9-based isothermal method of detection of specific DNA sequence
|
EP3795697A1
(en)
|
2014-02-04 |
2021-03-24 |
Jumpcode Genomics, Inc. |
Genome fractioning
|
HUE049634T2
(hu)
|
2014-02-11 |
2020-09-28 |
Univ Colorado Regents |
A CRISPR által lehetõvé tett multiplex génmanipuláció
|
US10287590B2
(en)
|
2014-02-12 |
2019-05-14 |
Dna2.0, Inc. |
Methods for generating libraries with co-varying regions of polynuleotides for genome modification
|
CN113265394A
(zh)
*
|
2014-02-13 |
2021-08-17 |
宝生物工程(美国) 有限公司 |
从核酸的初始集合中耗尽靶分子的方法、以及用于实践其的组合物和试剂盒
|
AU2015219167A1
(en)
|
2014-02-18 |
2016-09-08 |
Duke University |
Compositions for the inactivation of virus replication and methods of making and using the same
|
US10370680B2
(en)
*
|
2014-02-24 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Method of treating factor IX deficiency using nuclease-mediated targeted integration
|
CA3194412A1
(en)
|
2014-02-27 |
2015-09-03 |
Monsanto Technology Llc |
Compositions and methods for site directed genomic modification
|
CN103820454B
(zh)
*
|
2014-03-04 |
2016-03-30 |
上海金卫生物技术有限公司 |
CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA
|
WO2015134812A1
(en)
|
2014-03-05 |
2015-09-11 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
DK3115457T3
(da)
|
2014-03-05 |
2019-11-04 |
Univ Kobe Nat Univ Corp |
Fremgangsmåde til modificering af genomsekvens til specifikt at konvertere nukleinsyrebaser af målrettet dna-sekvens og molekylært kompleks til anvendelse i samme
|
EP3116997B1
(en)
|
2014-03-10 |
2019-05-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
CA3208184A1
(en)
*
|
2014-03-14 |
2015-09-17 |
Cibus Us Llc |
Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
EP3811970A1
(en)
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Regulatable chimeric antigen receptor
|
KR20160127832A
(ko)
|
2014-03-21 |
2016-11-04 |
젠자임 코포레이션 |
색소성 망막염의 유전자 치료
|
ES2870592T3
(es)
*
|
2014-03-24 |
2021-10-27 |
Immco Diagnostics Inc |
Detección mejorada de anticuerpos antinucleares y diagnóstico para trastornos autoinmunes sistémicos y no sistémicos
|
DK3122870T3
(da)
*
|
2014-03-25 |
2022-09-12 |
Ginkgo Bioworks Inc |
Fremgangsmåder og genetiske systemer til celleteknik
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
JP6669719B2
(ja)
*
|
2014-03-28 |
2020-03-18 |
アポセンス リミテッドAposense Ltd. |
分子の膜貫通送達のための化合物および方法
|
US11318206B2
(en)
|
2014-03-28 |
2022-05-03 |
Aposense Ltd |
Compounds and methods for trans-membrane delivery of molecules
|
WO2015153791A1
(en)
*
|
2014-04-01 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
|
WO2015153940A1
(en)
*
|
2014-04-03 |
2015-10-08 |
Massachusetts Institute Of Technology |
Methods and compositions for the production of guide rna
|
KR102487608B1
(ko)
|
2014-04-07 |
2023-01-12 |
노파르티스 아게 |
항-cd19 키메라 항원 수용체를 사용한 암의 치료
|
US11439712B2
(en)
|
2014-04-08 |
2022-09-13 |
North Carolina State University |
Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
|
WO2015161276A2
(en)
*
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
BR112016024565A2
(pt)
|
2014-04-25 |
2018-01-23 |
Children's Medical Center Corporation |
composições e métodos de tratar hemoglobinopatias
|
WO2015168404A1
(en)
*
|
2014-04-30 |
2015-11-05 |
Massachusetts Institute Of Technology |
Toehold-gated guide rna for programmable cas9 circuitry with rna input
|
PL3140269T3
(pl)
|
2014-05-09 |
2024-03-11 |
Yale University |
Cząstki pokryte hiperrozgałęzionym poliglicerolem oraz sposoby ich wytwarzania i zastosowania
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
WO2015175642A2
(en)
*
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
AU2015262993B2
(en)
|
2014-05-19 |
2019-11-07 |
Pfizer Inc. |
Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
|
WO2015179540A1
(en)
*
|
2014-05-20 |
2015-11-26 |
Regents Of The University Of Minnesota |
Method for editing a genetic sequence
|
EP3149171A1
(en)
|
2014-05-30 |
2017-04-05 |
The Board of Trustees of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
WO2015188056A1
(en)
*
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
SG11201609634YA
(en)
|
2014-06-06 |
2016-12-29 |
Regeneron Pharma |
Methods and compositions for modifying a targeted locus
|
CA2951707A1
(en)
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
US11274302B2
(en)
*
|
2016-08-17 |
2022-03-15 |
Diacarta Ltd |
Specific synthetic chimeric Xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency
|
HUE061007T2
(hu)
|
2014-06-11 |
2023-05-28 |
Univ Duke |
Gyors és dinamikus áramlásszabályozásra szolgáló összetételek és módszerek szintetikus matabolikus szelepek segítségével
|
CN106536056B
(zh)
|
2014-06-13 |
2021-07-16 |
儿童医学中心公司 |
分离线粒体的产品和方法
|
AU2015277180A1
(en)
*
|
2014-06-17 |
2017-01-12 |
Poseida Therapeutics, Inc. |
A method for directing proteins to specific loci in the genome and uses thereof
|
HUE049405T2
(hu)
|
2014-06-23 |
2020-09-28 |
Regeneron Pharma |
Nukleáz-közvetített DNS-összeállítás
|
KR102598819B1
(ko)
|
2014-06-23 |
2023-11-03 |
더 제너럴 하스피탈 코포레이션 |
서열결정에 의해 평가된 DSB의 게놈 전체에 걸친 비편향된 확인 (GUIDE-Seq)
|
RU2711740C2
(ru)
|
2014-06-26 |
2020-01-21 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для нацеленных генетических модификаций и способы их применения
|
US10676754B2
(en)
|
2014-07-11 |
2020-06-09 |
E I Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
WO2016011080A2
(en)
*
|
2014-07-14 |
2016-01-21 |
The Regents Of The University Of California |
Crispr/cas transcriptional modulation
|
EP3169702A4
(en)
*
|
2014-07-14 |
2018-04-18 |
The Regents of The University of California |
A protein tagging system for in vivo single molecule imaging and control of gene transcription
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
US20160053272A1
(en)
*
|
2014-07-18 |
2016-02-25 |
Whitehead Institute For Biomedical Research |
Methods Of Modifying A Sequence Using CRISPR
|
US20160053304A1
(en)
*
|
2014-07-18 |
2016-02-25 |
Whitehead Institute For Biomedical Research |
Methods Of Depleting Target Sequences Using CRISPR
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用cd33嵌合抗原受體治療癌症
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
CA2955386A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
CN112941065A
(zh)
*
|
2014-07-21 |
2021-06-11 |
亿明达股份有限公司 |
使用crispr-cas***的多核苷酸富集
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
US20160076093A1
(en)
*
|
2014-08-04 |
2016-03-17 |
University Of Washington |
Multiplex homology-directed repair
|
CN106922154B
(zh)
|
2014-08-06 |
2022-01-07 |
基因工具股份有限公司 |
使用空肠弯曲杆菌crispr/cas***衍生的rna引导的工程化核酸酶的基因编辑
|
WO2016022866A1
(en)
*
|
2014-08-07 |
2016-02-11 |
Agilent Technologies, Inc. |
Cis-blocked guide rna
|
US10513711B2
(en)
|
2014-08-13 |
2019-12-24 |
Dupont Us Holding, Llc |
Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
US11071289B2
(en)
|
2014-08-14 |
2021-07-27 |
Biocytogen Boston Corp |
DNA knock-in system
|
US9879270B2
(en)
*
|
2014-08-15 |
2018-01-30 |
Wisconsin Alumni Research Foundation |
Constructs and methods for genome editing and genetic engineering of fungi and protists
|
EP3633047B1
(en)
|
2014-08-19 |
2022-12-28 |
Pacific Biosciences of California, Inc. |
Method of sequencing nucleic acids based on an enrichment of nucleic acids
|
US10435685B2
(en)
|
2014-08-19 |
2019-10-08 |
Pacific Biosciences Of California, Inc. |
Compositions and methods for enrichment of nucleic acids
|
JP6806668B2
(ja)
*
|
2014-08-19 |
2021-01-06 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
核酸をプロービングおよびマッピングするためのrna誘導型システム
|
CN112410363A
(zh)
|
2014-08-19 |
2021-02-26 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
NZ728437A
(en)
|
2014-08-27 |
2018-02-23 |
Caribou Biosciences Inc |
Methods for increasing cas9-mediated engineering efficiency
|
EP3186375A4
(en)
|
2014-08-28 |
2019-03-13 |
North Carolina State University |
NEW CAS9 PROTEINS AND GUIDING ELEMENTS FOR DNA TARGETING AND THE GENOME EDITION
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
CA2956487A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
WO2016049024A2
(en)
*
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
US10370673B2
(en)
|
2014-09-26 |
2019-08-06 |
Purecircle Sdn Bhd |
Single nucleotide polymorphism (SNP) markers for stevia
|
WO2016054032A1
(en)
|
2014-09-29 |
2016-04-07 |
The Jackson Laboratory |
High efficiency, high throughput generation of genetically modified mammals by electroporation
|
WO2016054106A1
(en)
*
|
2014-09-29 |
2016-04-07 |
The Regents Of The University Of California |
SCAFFOLD RNAs
|
MX2017004306A
(es)
|
2014-10-01 |
2017-12-20 |
Eagle Biologics Inc |
Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
|
WO2016050512A1
(en)
|
2014-10-03 |
2016-04-07 |
Bayer Cropscience Nv |
Methods and means for increasing stress tolerance and biomass in plants
|
ES2741387T3
(es)
|
2014-10-15 |
2020-02-10 |
Regeneron Pharma |
Métodos y composiciones para generar o mantener células pluripotentes
|
EP3207131B1
(en)
*
|
2014-10-17 |
2022-09-28 |
Howard Hughes Medical Institute |
Genomic probes
|
US20170306306A1
(en)
*
|
2014-10-24 |
2017-10-26 |
Life Technologies Corporation |
Compositions and Methods for Enhancing Homologous Recombination
|
EP4219725A3
(en)
|
2014-10-31 |
2023-08-30 |
The Trustees of the University of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
WO2016070037A2
(en)
|
2014-10-31 |
2016-05-06 |
Massachusetts Institute Of Technology |
Massively parallel combinatorial genetics for crispr
|
WO2016073559A1
(en)
*
|
2014-11-05 |
2016-05-12 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing
|
EP3215611B1
(en)
|
2014-11-06 |
2019-08-21 |
E. I. du Pont de Nemours and Company |
Peptide-mediated delivery of rna-guided endonuclease into cells
|
EP3215617A2
(en)
|
2014-11-07 |
2017-09-13 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
US11470826B2
(en)
*
|
2014-11-17 |
2022-10-18 |
National University Corporation Tokyo Medical And Dental University |
Method of conveniently producing genetically modified non-human mammal with high efficiency
|
CN104531632A
(zh)
*
|
2014-11-18 |
2015-04-22 |
李云英 |
快速降解的Cas9-ODC422-461融合蛋白及其应用
|
AU2015349692B2
(en)
|
2014-11-21 |
2021-10-28 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide RNAs
|
EP3224353B9
(en)
*
|
2014-11-26 |
2023-08-09 |
Technology Innovation Momentum Fund (Israel) Limited Partnership |
Targeted elimination of bacterial genes
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
EP3227446A1
(en)
|
2014-12-01 |
2017-10-11 |
Novartis AG |
Compositions and methods for diagnosis and treatment of prostate cancer
|
AU2015355546B2
(en)
|
2014-12-03 |
2021-10-14 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
AU2015360502A1
(en)
|
2014-12-10 |
2017-06-29 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
CN107532162A
(zh)
*
|
2014-12-12 |
2018-01-02 |
托德·M·伍尔夫 |
用于利用寡核苷酸编辑细胞中核酸的组合物和方法
|
KR101796518B1
(ko)
*
|
2014-12-12 |
2017-11-14 |
한국한의학연구원 |
일체형 유전자 치료 유도만능줄기세포 제작방법
|
WO2016094874A1
(en)
*
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
AU2015362618B2
(en)
|
2014-12-16 |
2022-01-27 |
C3J Therapeutics, Inc. |
Compositions of and methods for in vitro viral genome engineering
|
WO2016099887A1
(en)
*
|
2014-12-17 |
2016-06-23 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for efficient gene editing in e. coli using guide rna/cas endonuclease systems in combination with circular polynucleotide modification templates
|
WO2016097751A1
(en)
*
|
2014-12-18 |
2016-06-23 |
The University Of Bath |
Method of cas9 mediated genome engineering
|
JP2017538427A
(ja)
|
2014-12-18 |
2017-12-28 |
インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド |
Crispr系組成物及び使用方法
|
MX2017008190A
(es)
|
2014-12-19 |
2018-03-23 |
Regeneron Pharma |
Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
EP3234111A1
(en)
|
2014-12-19 |
2017-10-25 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
CA2971444A1
(en)
|
2014-12-20 |
2016-06-23 |
Arc Bio, Llc |
Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
|
US9963710B2
(en)
|
2014-12-23 |
2018-05-08 |
Syngenta Participations Ag |
Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
|
WO2016106244A1
(en)
*
|
2014-12-24 |
2016-06-30 |
The Broad Institute Inc. |
Crispr having or associated with destabilization domains
|
WO2016109840A2
(en)
*
|
2014-12-31 |
2016-07-07 |
Synthetic Genomics, Inc. |
Compositions and methods for high efficiency in vivo genome editing
|
WO2016110453A1
(en)
*
|
2015-01-06 |
2016-07-14 |
Dsm Ip Assets B.V. |
A crispr-cas system for a filamentous fungal host cell
|
EP3245232B1
(en)
|
2015-01-12 |
2021-04-21 |
The Regents of The University of California |
Heterodimeric cas9 and methods of use thereof
|
MA41349A
(fr)
*
|
2015-01-14 |
2017-11-21 |
Univ Temple |
Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
|
US10059940B2
(en)
*
|
2015-01-27 |
2018-08-28 |
Minghong Zhong |
Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
|
EP3252162B1
(en)
|
2015-01-27 |
2023-03-01 |
Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences |
Method for conducting site-specific modification on entire plant via gene transient expression
|
WO2016123243A1
(en)
|
2015-01-28 |
2016-08-04 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
HRP20231022T1
(hr)
|
2015-01-28 |
2023-12-08 |
Caribou Biosciences, Inc. |
Hibridni polinukleotidi crispr dna/rna i načini uporabe
|
CN107429254B
(zh)
*
|
2015-01-30 |
2021-10-15 |
加利福尼亚大学董事会 |
原代造血细胞中的蛋白递送
|
ES2873400T3
(es)
*
|
2015-02-02 |
2021-11-03 |
Meiragtx Uk Ii Ltd |
Regulación de la expresión génica a través de la modulación mediada por un aptámero del corte y empalme alternativo
|
US10765699B2
(en)
|
2015-02-06 |
2020-09-08 |
National University Of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
WO2016133165A1
(ja)
*
|
2015-02-19 |
2016-08-25 |
国立大学法人徳島大学 |
Cas9 mRNAを哺乳動物の受精卵にエレクトロポレーションにより導入する方法
|
CN107532168A
(zh)
|
2015-02-23 |
2018-01-02 |
克里斯珀医疗股份公司 |
治疗血红蛋白病的材料和方法
|
US20180200387A1
(en)
|
2015-02-23 |
2018-07-19 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
US10968536B2
(en)
|
2015-02-25 |
2021-04-06 |
Jumpcode Genomics, Inc. |
Methods and compositions for sequencing
|
WO2016141224A1
(en)
|
2015-03-03 |
2016-09-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
WO2016142427A1
(en)
|
2015-03-10 |
2016-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method ank kit for reprogramming somatic cells
|
JP6588995B2
(ja)
|
2015-03-13 |
2019-10-09 |
ザ ジャクソン ラボラトリーThe Jackson Laboratory |
三構成要素CRISPR/Cas複合体系およびその使用
|
US11046952B2
(en)
*
|
2015-03-16 |
2021-06-29 |
The Broad Institute, Inc. |
Encoding of DNA vector identity via iterative hybridization detection of a barcode transcript
|
US10066256B2
(en)
|
2015-03-17 |
2018-09-04 |
Bio-Rad Laboratories, Inc. |
Detection of genome editing
|
CN107532177A
(zh)
|
2015-03-24 |
2018-01-02 |
加利福尼亚大学董事会 |
腺相关病毒变体及其使用方法
|
EP3274454B1
(en)
*
|
2015-03-25 |
2021-08-25 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
BR112017017260A2
(pt)
|
2015-03-27 |
2018-04-17 |
Du Pont |
construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo
|
WO2016161207A1
(en)
|
2015-03-31 |
2016-10-06 |
Exeligen Scientific, Inc. |
Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism
|
CA2981715A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
EP3284749A4
(en)
*
|
2015-04-13 |
2018-11-14 |
The University of Tokyo |
Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene
|
CA2982848A1
(en)
|
2015-04-15 |
2016-10-20 |
Synthetic Genomics, Inc. |
Algal chloroplastic srp54 mutants
|
US11674144B2
(en)
*
|
2015-04-16 |
2023-06-13 |
California Institute Of Technology |
Fractional regulation of transcription
|
US20180298068A1
(en)
|
2015-04-23 |
2018-10-18 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
KR102535217B1
(ko)
|
2015-04-24 |
2023-05-19 |
에디타스 메디신, 인코포레이티드 |
Cas9 분자/가이드 rna 분자 복합체의 평가
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
US11845928B2
(en)
*
|
2015-05-04 |
2023-12-19 |
Tsinghua University |
Methods and kits for fragmenting DNA
|
SG11201708706YA
(en)
|
2015-05-06 |
2017-11-29 |
Snipr Tech Ltd |
Altering microbial populations & modifying microbiota
|
WO2016182917A1
(en)
*
|
2015-05-08 |
2016-11-17 |
Children's Medical Center Corporation |
Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
|
US11253616B2
(en)
|
2017-09-06 |
2022-02-22 |
The Trustees Of The University Of Pennsylvania |
Small molecules for dual function positron emission tomography (PET) and cell suicide switches
|
WO2016182959A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
WO2016183402A2
(en)
*
|
2015-05-13 |
2016-11-17 |
President And Fellows Of Harvard College |
Methods of making and using guide rna for use with cas9 systems
|
CN107614680A
(zh)
*
|
2015-05-14 |
2018-01-19 |
南加利福尼亚大学 |
利用重组核酸内切酶***的最佳化基因编辑
|
WO2016186745A1
(en)
*
|
2015-05-15 |
2016-11-24 |
Ge Healthcare Dharmacon, Inc. |
Synthetic single guide rna for cas9-mediated gene editing
|
US11371050B2
(en)
|
2015-05-15 |
2022-06-28 |
Pioneer Hi-Bred International, Inc. |
Rapid characterization of Cas endonuclease systems, PAM sequences and guide RNA elements
|
EP3095870A1
(en)
|
2015-05-19 |
2016-11-23 |
Kws Saat Se |
Methods for the in planta transformation of plants and manufacturing processes and products based and obtainable therefrom
|
US10136649B2
(en)
|
2015-05-29 |
2018-11-27 |
North Carolina State University |
Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
UY36703A
(es)
|
2015-06-02 |
2016-12-30 |
Monsanto Technology Llc |
Composiciones y métodos para la administración de un polinucleótido en una planta
|
WO2016196655A1
(en)
|
2015-06-03 |
2016-12-08 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
EP3303585A4
(en)
|
2015-06-03 |
2018-10-31 |
Board of Regents of the University of Nebraska |
Dna editing using single-stranded dna
|
US20180296537A1
(en)
|
2015-06-05 |
2018-10-18 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
WO2016201047A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
US20160362667A1
(en)
|
2015-06-10 |
2016-12-15 |
Caribou Biosciences, Inc. |
CRISPR-Cas Compositions and Methods
|
CA2985714C
(en)
|
2015-06-12 |
2024-02-06 |
Lonza Walkersville, Inc. |
Methods for nuclear reprogramming using synthetic transcription factors
|
GB201510296D0
(en)
*
|
2015-06-12 |
2015-07-29 |
Univ Wageningen |
Thermostable CAS9 nucleases
|
DK3307872T3
(da)
|
2015-06-15 |
2023-10-23 |
Univ North Carolina State |
Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober
|
AU2016278959A1
(en)
|
2015-06-17 |
2018-01-18 |
The Uab Research Foundation |
CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
WO2016205703A1
(en)
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for genomic editing
|
EP3929286A1
(en)
*
|
2015-06-17 |
2021-12-29 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
IL284808B
(en)
|
2015-06-18 |
2022-07-01 |
Broad Inst Inc |
Mutations in the crispr enzyme that reduce unintended effects
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
WO2016205749A1
(en)
*
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
WO2017004279A2
(en)
*
|
2015-06-29 |
2017-01-05 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
JP2018519811A
(ja)
|
2015-06-29 |
2018-07-26 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾crispr rna及び修飾単一crispr rnaならびにその使用
|
JP6765665B2
(ja)
*
|
2015-07-13 |
2020-10-07 |
国立研究開発法人農業・食品産業技術総合研究機構 |
不稔化植物、不稔化植物の作出方法、及びベクター
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
JP7044373B2
(ja)
|
2015-07-15 |
2022-03-30 |
ラトガース,ザ ステート ユニバーシティ オブ ニュージャージー |
ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
|
WO2017015101A1
(en)
*
|
2015-07-17 |
2017-01-26 |
University Of Washington |
Methods for maximizing the efficiency of targeted gene correction
|
US10676735B2
(en)
|
2015-07-22 |
2020-06-09 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
WO2017023803A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
WO2017024047A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Emendobio Inc. |
Compositions and methods for increasing nuclease induced recombination rate in cells
|
EP3331905B1
(en)
|
2015-08-06 |
2022-10-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
CN108271387B
(zh)
|
2015-08-07 |
2023-06-27 |
箭头药业股份有限公司 |
乙型肝炎病毒感染的RNAi疗法
|
US9580727B1
(en)
*
|
2015-08-07 |
2017-02-28 |
Caribou Biosciences, Inc. |
Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
|
EP3334746B1
(en)
|
2015-08-14 |
2021-11-24 |
The University Of Sydney |
Connexin 45 inhibition for therapy
|
KR102127418B1
(ko)
*
|
2015-08-14 |
2020-06-26 |
인스티튜트 오브 제네틱스 앤드 디벨롭멘털 바이오롤지, 차이니즈 아카데미 오브 사이언시스 |
부위-특이적인 뉴클레오티드 치환을 통해 글리포세이트-내성 벼를 수득하는 방법
|
CN108135941B
(zh)
|
2015-08-19 |
2021-07-27 |
儿研所儿童医学中心 |
用于治疗移植物抗宿主病的组合物和方法
|
DK3337898T3
(da)
|
2015-08-19 |
2021-10-18 |
Arc Bio Llc |
Indfangning af nukleinsyrer ved anvendelse af et nukleinsyre-styret nuclease-baseret system
|
US11427817B2
(en)
*
|
2015-08-25 |
2022-08-30 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using RNA-guided endonucleases
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
ES2773072T3
(es)
|
2015-08-28 |
2020-07-09 |
Pioneer Hi Bred Int |
Transformación de plantas mediada por Ochrobactrum
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
JP6799586B2
(ja)
|
2015-08-28 |
2020-12-16 |
ザ ジェネラル ホスピタル コーポレイション |
遺伝子操作CRISPR−Cas9ヌクレアーゼ
|
WO2017040709A1
(en)
|
2015-08-31 |
2017-03-09 |
Caribou Biosciences, Inc. |
Directed nucleic acid repair
|
CN107922949A
(zh)
|
2015-08-31 |
2018-04-17 |
安捷伦科技有限公司 |
用于通过同源重组的基于crispr/cas的基因组编辑的化合物和方法
|
US11453864B2
(en)
*
|
2015-09-08 |
2022-09-27 |
University Of Massachusetts |
DNase H activity of Neisseria meningitidis Cas9
|
CN108348167B
(zh)
*
|
2015-09-09 |
2022-06-03 |
普梭梅根公司 |
用于脑-颅面健康相关病症的源自微生物群系的诊断及治疗方法和***
|
CN108271384B
(zh)
*
|
2015-09-09 |
2022-04-15 |
国立大学法人神户大学 |
用于特异性转变靶向dna序列的核酸碱基的革兰氏阳性菌的基因组序列的转变方法、及其使用的分子复合体
|
CN108348166B
(zh)
*
|
2015-09-09 |
2022-06-03 |
普梭梅根公司 |
用于与抗生素使用相关的感染性疾病及其它健康状况的源自微生物群系的诊断及治疗方法和***
|
WO2017044776A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Texas Tech University System |
Single-guide rna (sgrna) with improved knockout efficiency
|
KR20180043369A
(ko)
|
2015-09-11 |
2018-04-27 |
더 제너럴 하스피탈 코포레이션 |
뉴클레아제 dsb의 완전한 호출 및 시퀀싱(find-seq)
|
CN108271360B
(zh)
|
2015-09-14 |
2023-01-24 |
得克萨斯州大学***董事会 |
亲脂阳离子树枝状聚合物及其用途
|
EP3352795B1
(en)
*
|
2015-09-21 |
2020-08-12 |
The Regents of The University of California |
Compositions and methods for target nucleic acid modification
|
CA2999500A1
(en)
|
2015-09-24 |
2017-03-30 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
EP3356533A1
(en)
*
|
2015-09-28 |
2018-08-08 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
US20170088828A1
(en)
*
|
2015-09-29 |
2017-03-30 |
Agenovir Corporation |
Compositions and methods for treatment of latent viral infections
|
JP2018529353A
(ja)
|
2015-09-30 |
2018-10-11 |
ザ ジェネラル ホスピタル コーポレイション |
配列決定法による切断事象の包括的生体外報告(CIRCLE−seq)
|
WO2017059241A1
(en)
|
2015-10-02 |
2017-04-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
WO2017062855A1
(en)
*
|
2015-10-09 |
2017-04-13 |
Monsanto Technology Llc |
Novel rna-guided nucleases and uses thereof
|
DK3362560T3
(da)
|
2015-10-12 |
2022-11-07 |
Dupont Us Holding Llc |
Beskyttede dna-templater til genmodificering og forøget homolog rekombination i celler og fremgangsmåder til anvendelse
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
US9862941B2
(en)
|
2015-10-14 |
2018-01-09 |
Pioneer Hi-Bred International, Inc. |
Single cell microfluidic device
|
CN108290939B
(zh)
|
2015-10-16 |
2023-01-13 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
FR3042506B1
(fr)
*
|
2015-10-16 |
2018-11-30 |
IFP Energies Nouvelles |
Outil genetique de transformation de bacteries clostridium
|
MX2018004809A
(es)
|
2015-10-20 |
2018-06-08 |
Pionner Hi Bred Int Inc |
Metodos y composiciones para la modificacion genomica exenta de marcadores.
|
WO2017068077A1
(en)
*
|
2015-10-20 |
2017-04-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and products for genetic engineering
|
WO2017070605A1
(en)
*
|
2015-10-22 |
2017-04-27 |
The Broad Institute Inc. |
Type vi-b crispr enzymes and systems
|
WO2017068120A1
(en)
|
2015-10-22 |
2017-04-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Endonuclease-barcoding
|
EP3350327B1
(en)
|
2015-10-23 |
2018-09-26 |
Caribou Biosciences, Inc. |
Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
|
US10167457B2
(en)
|
2015-10-23 |
2019-01-01 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
AU2016344609B2
(en)
|
2015-10-28 |
2022-05-12 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of duchenne muscular dystrophy
|
JP6882282B2
(ja)
|
2015-11-03 |
2021-06-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
三次元核酸含有マトリックスの立体撮像のための方法と装置
|
EP3371306B8
(en)
|
2015-11-04 |
2023-02-22 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
EP3370513A1
(en)
|
2015-11-06 |
2018-09-12 |
The Jackson Laboratory |
Large genomic dna knock-in and uses thereof
|
MX2018005332A
(es)
|
2015-11-06 |
2018-11-09 |
Crispr Therapeutics Ag |
Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a.
|
BR112018007796A2
(pt)
|
2015-11-06 |
2018-10-30 |
Du Pont |
plantas de soja, partes de plantas de soja ou sementes de soja, método para selecionar uma célula de soja, métodos de seleção de uma célula de soja e de produção de um locus e molécula de ácido nucleico
|
WO2017081288A1
(en)
|
2015-11-11 |
2017-05-18 |
Lonza Ltd |
Crispr-associated (cas) proteins with reduced immunogenicity
|
WO2017083368A1
(en)
*
|
2015-11-12 |
2017-05-18 |
Pfizer Inc. |
Tissue-specific genome engineering using crispr-cas9
|
WO2017083766A1
(en)
*
|
2015-11-13 |
2017-05-18 |
Massachusetts Institute Of Technology |
High-throughput crispr-based library screening
|
IL259441B2
(en)
|
2015-11-16 |
2024-01-01 |
Res Inst Nationwide Childrens Hospital |
Materials and methods for the treatment of titin-based myopathies and other titinopathy
|
US10669320B2
(en)
|
2015-11-18 |
2020-06-02 |
The Regents Of The University Of Michigan |
Mps1 and KNL1 phosphorylation system
|
JP6923205B2
(ja)
|
2015-11-27 |
2021-08-18 |
国立大学法人神戸大学 |
標的化したdna配列の核酸塩基を特異的に変換する、単子葉植物のゲノム配列の変換方法、及びそれに用いる分子複合体
|
EP3383411A4
(en)
|
2015-11-30 |
2019-07-03 |
Flagship Pioneering Innovations V, Inc. |
METHODS AND COMPOSITIONS RELATING TO CHONDRISOMES FROM CULTIVATED CELLS
|
US10933128B2
(en)
|
2015-11-30 |
2021-03-02 |
Joseph E. Kovarik |
Method and system for protecting honey bees from pesticides
|
US11529412B2
(en)
|
2015-11-30 |
2022-12-20 |
Seed Health, Inc. |
Method and system for protecting honey bees from pesticides
|
US10675347B2
(en)
|
2015-11-30 |
2020-06-09 |
Joseph E. Kovarik |
Method and system for protecting honey bees from fipronil pesticides
|
US10086024B2
(en)
|
2015-11-30 |
2018-10-02 |
Joseph E. Kovarik |
Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
|
US10568916B2
(en)
|
2015-11-30 |
2020-02-25 |
Joseph E. Kovarik |
Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
|
WO2017093804A2
(en)
|
2015-12-01 |
2017-06-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
US10946042B2
(en)
|
2015-12-01 |
2021-03-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for selective phagocytosis of human cancer cells
|
US9771600B2
(en)
*
|
2015-12-04 |
2017-09-26 |
Caribou Biosciences, Inc. |
Engineered nucleic acid-targeting nucleic acids
|
BR112018011503A2
(pt)
|
2015-12-07 |
2018-12-04 |
Zymergen Inc |
promotores da corynebacterium glutamicum
|
CN109310784B
(zh)
|
2015-12-07 |
2022-08-19 |
阿克生物公司 |
用于制备和使用指导核酸的方法和组合物
|
US11208649B2
(en)
|
2015-12-07 |
2021-12-28 |
Zymergen Inc. |
HTP genomic engineering platform
|
US9988624B2
(en)
|
2015-12-07 |
2018-06-05 |
Zymergen Inc. |
Microbial strain improvement by a HTP genomic engineering platform
|
EP3387134B1
(en)
|
2015-12-11 |
2020-10-14 |
Danisco US Inc. |
Methods and compositions for enhanced nuclease-mediated genome modification and reduced off-target site effects
|
US20200263165A1
(en)
*
|
2015-12-18 |
2020-08-20 |
Danisco Us Inc. |
Methods and compositions for polymerase ii (pol-ii) based guide rna expression
|
US20190075770A1
(en)
*
|
2015-12-18 |
2019-03-14 |
Japan Science And Technology Agency |
Genetic modification non-human organism, egg cells, fertilized eggs, and method for modifying target genes
|
WO2017106767A1
(en)
*
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
EP3708665A1
(en)
|
2015-12-18 |
2020-09-16 |
Danisco US Inc. |
Methods and compositions for t-rna based guide rna expression
|
EP3390624A4
(en)
|
2015-12-18 |
2019-07-10 |
The Regents of The University of California |
MODIFIED POLYPEPTIDES AND METHOD OF USE THEREOF
|
CA3009123A1
(en)
|
2015-12-18 |
2017-06-22 |
Oncosec Medical Incorporated |
Plasmid constructs for heterologous protein expression and methods of use
|
WO2017112620A1
(en)
|
2015-12-22 |
2017-06-29 |
North Carolina State University |
Methods and compositions for delivery of crispr based antimicrobials
|
BR112018012894A2
(pt)
|
2015-12-23 |
2018-12-04 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal
|
US11026969B2
(en)
|
2015-12-23 |
2021-06-08 |
Fred Hutchinson Cancer Research Center |
High affinity T cell receptors and uses thereof
|
RU2018127657A
(ru)
|
2015-12-30 |
2020-01-31 |
Новартис Аг |
Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
|
US11441146B2
(en)
|
2016-01-11 |
2022-09-13 |
Christiana Care Health Services, Inc. |
Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system
|
MY196175A
(en)
*
|
2016-01-11 |
2023-03-20 |
Univ Leland Stanford Junior |
Chimeric Proteins And Methods Of Regulating Gene Expression
|
MY194127A
(en)
*
|
2016-01-11 |
2022-11-14 |
Univ Leland Stanford Junior |
Chimeric proteins and methods of immunotherapy
|
US11427837B2
(en)
*
|
2016-01-12 |
2022-08-30 |
The Regents Of The University Of California |
Compositions and methods for enhanced genome editing
|
EP3402327A1
(en)
|
2016-01-15 |
2018-11-21 |
The Jackson Laboratory |
Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
|
EP3199632A1
(en)
|
2016-01-26 |
2017-08-02 |
ACIB GmbH |
Temperature-inducible crispr/cas system
|
BR112018015348A2
(pt)
|
2016-01-26 |
2018-12-18 |
Pioneer Hi Bred Int |
método para obter uma planta de milho ceroso, planta, semente, polinucleotídeo-guia e método para produzir uma planta híbrida de milho ceroso
|
CN109072224B
(zh)
*
|
2016-01-30 |
2022-07-15 |
株式会社博纳克 |
人工单导rna及其用途
|
US20190038771A1
(en)
|
2016-02-02 |
2019-02-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
BR112018016278A2
(pt)
|
2016-02-09 |
2019-01-02 |
Cibus Europe Bv |
métodos e composições para aumentar a eficiência da modificação do gene direcionada usando reparação de gene mediada por oligonucleotídeo
|
ES2835101T3
(es)
*
|
2016-02-10 |
2021-06-21 |
Univ Michigan Regents |
Detección de ácidos nucleicos
|
US11339427B2
(en)
|
2016-02-12 |
2022-05-24 |
Jumpcode Genomics, Inc. |
Method for target specific RNA transcription of DNA sequences
|
US10876129B2
(en)
|
2016-02-12 |
2020-12-29 |
Ceres, Inc. |
Methods and materials for high throughput testing of mutagenized allele combinations
|
US9896696B2
(en)
|
2016-02-15 |
2018-02-20 |
Benson Hill Biosystems, Inc. |
Compositions and methods for modifying genomes
|
EP3416976A2
(en)
|
2016-02-16 |
2018-12-26 |
Yale University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
US20200308590A1
(en)
|
2016-02-16 |
2020-10-01 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
EP3416689B1
(en)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
EP3420080B1
(en)
|
2016-02-22 |
2019-08-21 |
Caribou Biosciences, Inc. |
Methods for modulating dna repair outcomes
|
CN105646719B
(zh)
*
|
2016-02-24 |
2019-12-20 |
无锡市妇幼保健院 |
一种高效定点转基因的工具及其应用
|
US11530253B2
(en)
|
2016-02-25 |
2022-12-20 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
|
SG11201807025SA
(en)
*
|
2016-02-26 |
2018-09-27 |
Lanzatech New Zealand Ltd |
Crispr/cas systems for c-1 fixing bacteria
|
US10538750B2
(en)
|
2016-02-29 |
2020-01-21 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by CRISPR proteins
|
WO2017155714A1
(en)
|
2016-03-11 |
2017-09-14 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 systems and methods of use
|
EP3699280A3
(en)
|
2016-03-11 |
2020-11-18 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 systems and methods of use
|
WO2017155715A1
(en)
|
2016-03-11 |
2017-09-14 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 systems and methods of use
|
US11530394B2
(en)
*
|
2016-03-15 |
2022-12-20 |
University Of Massachusetts |
Anti-CRISPR compounds and methods of use
|
CN109414414A
(zh)
|
2016-03-16 |
2019-03-01 |
戴维·格拉德斯通研究所 |
用于治疗肥胖症和/或糖尿病以及用于鉴定候选治疗剂的方法和组合物
|
EP3429632B1
(en)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of hereditary haemochromatosis
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
EP3433364A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
WO2017165826A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
US11236313B2
(en)
|
2016-04-13 |
2022-02-01 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
EP3443081A4
(en)
*
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
CN109312308A
(zh)
*
|
2016-04-14 |
2019-02-05 |
亿阳集团美国硅谷公司 |
通过使用核酸酶来进行人神经干细胞的基因组编辑
|
EP4180519A1
(en)
|
2016-04-15 |
2023-05-17 |
Memorial Sloan Kettering Cancer Center |
Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
|
WO2017181119A2
(en)
|
2016-04-15 |
2017-10-19 |
Novartis Ag |
Compositions and methods for selective protein expression
|
US20200172935A1
(en)
*
|
2016-04-16 |
2020-06-04 |
Ohio State Innovation Foundation |
Modified cpf1 mrna, modified guide rna, and uses thereof
|
SG10202010261YA
(en)
|
2016-04-18 |
2020-11-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
MX2018012873A
(es)
*
|
2016-04-22 |
2019-08-05 |
Intellia Therapeutics Inc |
Composiciones y métodos para el tratar enfermedades asociadas con repeticiones de trinucleótidos en el factor de transcripción cuatro.
|
CA3022290A1
(en)
|
2016-04-25 |
2017-11-02 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
EP3448996A1
(en)
|
2016-04-26 |
2019-03-06 |
Massachusetts Institute of Technology |
Extensible recombinase cascades
|
WO2017189870A1
(en)
|
2016-04-27 |
2017-11-02 |
Massachusetts Institute Of Technology |
Stable nanoscale nucleic acid assemblies and methods thereof
|
WO2017189914A1
(en)
|
2016-04-27 |
2017-11-02 |
Massachusetts Institute Of Technology |
Sequence-controlled polymer random access memory storage
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
CN109414449A
(zh)
*
|
2016-05-06 |
2019-03-01 |
托德·M·伍尔夫 |
利用和不利用可设计核酸酶编辑基因组的改进方法
|
US10568840B2
(en)
|
2016-05-06 |
2020-02-25 |
The Brigham And Women's Hospital, Inc. |
Self assembled gels for controlled delivery of encapsulated agents to cartilage
|
WO2017197128A1
(en)
|
2016-05-11 |
2017-11-16 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
US11499158B2
(en)
|
2016-05-13 |
2022-11-15 |
Kaneka Corporation |
Method for modifying plant
|
EP3456825A4
(en)
*
|
2016-05-13 |
2020-03-18 |
Kaneka Corporation |
METHOD FOR PLANT GENE EDITING
|
CN109152343A
(zh)
|
2016-05-13 |
2019-01-04 |
株式会社钟化 |
转化植物的制备方法
|
RU2021106817A
(ru)
|
2016-05-20 |
2021-04-06 |
Регенерон Фармасьютикалс, Инк. |
Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
|
AU2017268842B2
(en)
*
|
2016-05-27 |
2022-08-11 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
EP3463484A4
(en)
|
2016-05-27 |
2019-10-30 |
The Regents of the University of California |
METHOD AND COMPOSITIONS FOR TARGETING RNA POLYMERASES AND NON-CODING RNA BIOGENESIS AT SPECIFIC LOCI
|
EP3907286A1
(en)
*
|
2016-06-02 |
2021-11-10 |
Sigma-Aldrich Co., LLC |
Using programmable dna binding proteins to enhance targeted genome modification
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
WO2017222834A1
(en)
*
|
2016-06-10 |
2017-12-28 |
City Of Hope |
Compositions and methods for mitochondrial genome editing
|
KR20190016970A
(ko)
|
2016-06-14 |
2019-02-19 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
식물 게놈 변형을 위한 cpf1 엔도뉴클레아제의 용도
|
WO2017217768A1
(ko)
*
|
2016-06-15 |
2017-12-21 |
주식회사 툴젠 |
온타겟 및 오프타겟의 다중 타겟 시스템을 이용하는, 표적 특이적 유전자 가위 스크리닝 방법 및 이의 용도
|
US10337051B2
(en)
|
2016-06-16 |
2019-07-02 |
The Regents Of The University Of California |
Methods and compositions for detecting a target RNA
|
KR20230156150A
(ko)
*
|
2016-06-17 |
2023-11-13 |
더 브로드 인스티튜트, 인코퍼레이티드 |
제vi형 crispr 오솔로그 및 시스템
|
US20190100745A1
(en)
|
2016-06-20 |
2019-04-04 |
Pioneer Hi-Bred International, Inc. |
Novel cas systems and methods of use
|
US11293021B1
(en)
|
2016-06-23 |
2022-04-05 |
Inscripta, Inc. |
Automated cell processing methods, modules, instruments, and systems
|
US10017760B2
(en)
|
2016-06-24 |
2018-07-10 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
EP3474849A4
(en)
|
2016-06-27 |
2020-07-29 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF DIABETES
|
CA3029271A1
(en)
|
2016-06-28 |
2018-01-04 |
Cellectis |
Altering expression of gene products in plants through targeted insertion of nucleic acid sequences
|
US11564997B2
(en)
|
2016-06-29 |
2023-01-31 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
KR102345898B1
(ko)
|
2016-06-30 |
2022-01-03 |
지머젠 인코포레이티드 |
글루코오스 투과 효소 라이브러리를 생성하는 방법 및 이의 용도
|
JP2019519242A
(ja)
|
2016-06-30 |
2019-07-11 |
ザイマージェン インコーポレイテッド |
細菌ヘモグロビンライブラリーを生成するための方法およびその使用
|
CA3029141A1
(en)
|
2016-07-06 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of pain related disorders
|
US11801313B2
(en)
|
2016-07-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
CA3030837A1
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
CA3030587A1
(en)
|
2016-07-15 |
2018-01-18 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
WO2018015444A1
(en)
|
2016-07-22 |
2018-01-25 |
Novozymes A/S |
Crispr-cas9 genome editing with multiple guide rnas in filamentous fungi
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
CN106191043B
(zh)
*
|
2016-07-26 |
2019-07-02 |
吉林大学 |
一种基因片段、载体pPlasmid-Clearance及应用
|
EP4230648A3
(en)
|
2016-07-28 |
2023-10-18 |
Regeneron Pharmaceuticals, Inc. |
Gpr156 variants and uses thereof
|
CA3031206A1
(en)
|
2016-07-29 |
2018-02-01 |
Regeneron Pharmaceuticals, Inc. |
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
|
BR112019001887A2
(pt)
|
2016-08-02 |
2019-07-09 |
Editas Medicine Inc |
composições e métodos para o tratamento de doença associada a cep290
|
IL308426A
(en)
|
2016-08-03 |
2024-01-01 |
Harvard College |
Adenosine nuclear base editors and their uses
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
CN109804066A
(zh)
*
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
KR101710026B1
(ko)
|
2016-08-10 |
2017-02-27 |
주식회사 무진메디 |
Cas9 단백질 및 가이드 RNA의 혼성체를 함유하는 나노 리포좀 전달체 조성물
|
WO2018031950A1
(en)
|
2016-08-12 |
2018-02-15 |
Caribou Biosciences, Inc. |
Protein engineering methods
|
EP3500669A4
(en)
*
|
2016-08-16 |
2020-01-22 |
The Regents of the University of California |
METHOD FOR FINDING LOW FREQUENCY SEQUENCES BY HYBRIDIZATION (FLASH)
|
US11434476B2
(en)
|
2016-08-19 |
2022-09-06 |
Whitehead Institute For Biomedical Research |
Methods of editing DNA methylation
|
EP3500271A4
(en)
*
|
2016-08-19 |
2020-05-13 |
Bluebird Bio, Inc. |
GENOME EDITING ACTIVATORS
|
CN109963945A
(zh)
*
|
2016-08-20 |
2019-07-02 |
阿维利诺美国实验室股份有限公司 |
单一向导rna、crispr/cas9***及其使用方法
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
EP3503927A1
(en)
|
2016-08-29 |
2019-07-03 |
The Regents of the University of California |
Topical formulations based on ionic species for skin treatment
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
CN106399311A
(zh)
*
|
2016-09-07 |
2017-02-15 |
同济大学 |
用于Chip‑seq全基因组结合谱的内源蛋白标记的方法
|
US20190242908A1
(en)
|
2016-09-08 |
2019-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating nephrotic syndrome
|
EP3510151A4
(en)
|
2016-09-09 |
2020-04-15 |
The Board of Trustees of the Leland Stanford Junior University |
HIGH-THROUGHPUT PRECISION GENE EDITING
|
EP3512535A4
(en)
|
2016-09-13 |
2020-05-06 |
The Jackson Laboratory |
TARGETED IMPROVED DNA DEMETHYLATION
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
CA3035075A1
(en)
|
2016-09-23 |
2018-03-29 |
Fred Hutchinson Cancer Research Center |
Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
|
EP3519577A1
(en)
|
2016-09-28 |
2019-08-07 |
Novartis AG |
Porous membrane-based macromolecule delivery system
|
GB201616590D0
(en)
|
2016-09-29 |
2016-11-16 |
Oxford Nanopore Technologies Limited |
Method
|
WO2018060238A1
(en)
*
|
2016-09-29 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Method to analyze and optimize gene editing modules and delivery approaches
|
KR20230169449A
(ko)
*
|
2016-09-30 |
2023-12-15 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
|
EA201990861A1
(ru)
|
2016-09-30 |
2019-09-30 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
WO2018069232A1
(en)
|
2016-10-10 |
2018-04-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of having cardiac hypertrophy
|
EP3525933A1
(en)
|
2016-10-11 |
2019-08-21 |
The Regents of the University of California |
Systems and methods to encapsulate and preserve organic matter for analysis
|
BR112019007327A2
(pt)
|
2016-10-13 |
2019-07-02 |
Pioneer Hi Bred Int |
método para obter uma célula vegetal, célula vegetal, planta, semente, polinucleotídeo-guia
|
AU2017342543A1
(en)
|
2016-10-14 |
2019-05-02 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
EP3525832A4
(en)
|
2016-10-14 |
2020-04-29 |
The General Hospital Corp. |
SITE SPECIFIC NUCLEASES WITH EPIGENETIC REGULATION
|
GB201617559D0
(en)
|
2016-10-17 |
2016-11-30 |
University Court Of The University Of Edinburgh The |
Swine comprising modified cd163 and associated methods
|
GB2605540B
(en)
|
2016-10-18 |
2022-12-21 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
US11766400B2
(en)
|
2016-10-24 |
2023-09-26 |
Yale University |
Biodegradable contraceptive implants
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
WO2018080573A1
(en)
|
2016-10-28 |
2018-05-03 |
Massachusetts Institute Of Technology |
Crispr/cas global regulator screening platform
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
US11732258B2
(en)
*
|
2016-11-02 |
2023-08-22 |
President And Fellows Of Harvard College |
Engineered guide RNA sequences for in situ detection and sequencing
|
WO2018081978A1
(zh)
*
|
2016-11-03 |
2018-05-11 |
深圳华大基因研究院 |
提高基因编辑效率的方法和***
|
WO2018144097A1
(en)
|
2016-11-04 |
2018-08-09 |
Akeagen Llc |
Genetically modified non-human animals and methods for producing heavy chain-only antibodies
|
CA3042259A1
(en)
|
2016-11-04 |
2018-05-11 |
Flagship Pioneering Innovations V. Inc. |
Novel plant cells, plants, and seeds
|
EP3538140A1
(en)
|
2016-11-14 |
2019-09-18 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
KR20190089175A
(ko)
*
|
2016-11-18 |
2019-07-30 |
진에딧 인코포레이티드 |
표적 핵산 변형을 위한 조성물 및 방법
|
JP2019536480A
(ja)
|
2016-11-22 |
2019-12-19 |
ナショナル ユニバーシティ オブ シンガポール |
T細胞悪性腫瘍の免疫療法のためのcd7発現およびキメラ抗原受容体の遮断
|
CA3044531A1
(en)
|
2016-11-28 |
2018-05-31 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing
|
EP3548894B1
(en)
|
2016-12-02 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
US9816093B1
(en)
|
2016-12-06 |
2017-11-14 |
Caribou Biosciences, Inc. |
Engineered nucleic acid-targeting nucleic acids
|
CA3046220A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
WO2018111834A1
(en)
|
2016-12-13 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
CN110312792B
(zh)
*
|
2016-12-14 |
2024-04-09 |
瓦赫宁根大学 |
热稳定的Cas9核酸酶
|
US10975388B2
(en)
|
2016-12-14 |
2021-04-13 |
Ligandal, Inc. |
Methods and compositions for nucleic acid and protein payload delivery
|
US20200085758A1
(en)
|
2016-12-16 |
2020-03-19 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
WO2018118585A1
(en)
*
|
2016-12-22 |
2018-06-28 |
Agenovir Corporation |
Antiviral compositions
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
WO2018126087A1
(en)
|
2016-12-29 |
2018-07-05 |
Applied Stemcell, Inc. |
Gene editing method using virus
|
US11859219B1
(en)
|
2016-12-30 |
2024-01-02 |
Flagship Pioneering Innovations V, Inc. |
Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
|
EP3342868B1
(en)
|
2016-12-30 |
2019-12-25 |
Systasy Bioscience GmbH |
Constructs and screening methods
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
US20190330658A1
(en)
|
2017-01-05 |
2019-10-31 |
Rutgers, The State University |
Targeted gene editing platform independent of dna double strand break and uses thereof
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
AU2018205898B2
(en)
|
2017-01-09 |
2020-12-10 |
Aposense Ltd. |
Compounds and methods for trans-membrane delivery of molecules
|
EP3565891B1
(en)
|
2017-01-09 |
2023-04-12 |
Whitehead Institute for Biomedical Research |
Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
|
CA3048501A1
(en)
|
2017-01-10 |
2018-07-19 |
Christiana Care Health Services, Inc. |
Methods for in vitro site-directed mutagenesis using gene editing technologies
|
JP7215716B2
(ja)
*
|
2017-01-13 |
2023-01-31 |
学校法人自治医科大学 |
肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのaavベクター
|
EP3571304A4
(en)
|
2017-01-20 |
2020-08-19 |
The Regents of the University of California |
TARGETED ACTIVATION IN PLANTS
|
IL301053A
(en)
|
2017-01-23 |
2023-05-01 |
Regeneron Pharma |
HSD17B13 variants and their uses
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
WO2018140362A1
(en)
|
2017-01-26 |
2018-08-02 |
The Regents Of The University Of California |
Targeted gene demethylation in plants
|
SG11201906795SA
(en)
|
2017-01-28 |
2019-08-27 |
Inari Agriculture Inc |
Novel plant cells, plants, and seeds
|
US20190375815A1
(en)
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
JP2020506702A
(ja)
|
2017-02-02 |
2020-03-05 |
カーギル インコーポレイテッド |
C6−c10脂肪酸誘導体を生成する遺伝子組み換え細胞
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
CA3052635A1
(en)
|
2017-02-06 |
2018-11-08 |
Zymergen Inc. |
Engineered biosynthetic pathways for production of tyramine by fermentation
|
CN111386263A
(zh)
|
2017-02-08 |
2020-07-07 |
达纳-法伯癌症研究所有限公司 |
调节嵌合抗原受体
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
CA3049989A1
(en)
|
2017-02-10 |
2018-08-16 |
Zymergen Inc. |
A modular universal plasmid design strategy for the assembly and editing of multiple dna constructs for multiple hosts
|
JP6878607B2
(ja)
|
2017-02-21 |
2021-05-26 |
デューク ユニバーシティ |
ロバストな動的な代謝コントロールの為の組成物及び方法
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
CA3054031A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
US20200216857A1
(en)
|
2017-02-22 |
2020-07-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
CN110913881A
(zh)
*
|
2017-03-14 |
2020-03-24 |
加利福尼亚大学董事会 |
工程化crispr cas9免疫隐身
|
MX2019010972A
(es)
|
2017-03-15 |
2019-12-02 |
Hutchinson Fred Cancer Res |
Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
|
WO2018167119A1
(en)
|
2017-03-15 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
|
JP7191388B2
(ja)
|
2017-03-23 |
2022-12-19 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
核酸によってプログラム可能なdna結合蛋白質を含む核酸塩基編集因子
|
WO2018172556A1
(en)
*
|
2017-03-24 |
2018-09-27 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
EP3600269A1
(en)
|
2017-03-24 |
2020-02-05 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Gfi1 inhibitors for the treatment of hyperglycemia
|
WO2018172508A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
PT3526324T
(pt)
|
2017-03-28 |
2021-10-20 |
Locanabio Inc |
Proteína associada a crispr (cas)
|
EP3600308A1
(en)
|
2017-03-30 |
2020-02-05 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of mitochondrial genetic diseases
|
US11661624B2
(en)
|
2017-03-30 |
2023-05-30 |
Pioneer Hi-Bred International, Inc. |
Methods of identifying and characterizing gene editing variations in nucleic acids
|
WO2018187493A1
(en)
|
2017-04-04 |
2018-10-11 |
Yale University |
Compositions and methods for in utero delivery
|
CN110325649A
(zh)
|
2017-04-11 |
2019-10-11 |
雷杰纳荣制药公司 |
用于筛选羟基类固醇(17-β)脱氢酶(HSD17B)家族成员的调节剂的活性的测定法
|
WO2018195129A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
US11834670B2
(en)
*
|
2017-04-19 |
2023-12-05 |
Global Life Sciences Solutions Usa Llc |
Site-specific DNA modification using a donor DNA repair template having tandem repeat sequences
|
US11591589B2
(en)
|
2017-04-21 |
2023-02-28 |
The General Hospital Corporation |
Variants of Cpf1 (Cas12a) with altered PAM specificity
|
DK3612174T3
(da)
|
2017-04-21 |
2023-05-08 |
Inst Nat Sante Rech Med |
Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion
|
US11667677B2
(en)
|
2017-04-21 |
2023-06-06 |
The General Hospital Corporation |
Inducible, tunable, and multiplex human gene regulation using CRISPR-Cpf1
|
US11732251B2
(en)
|
2017-04-24 |
2023-08-22 |
Dupont Nutrition Biosciences Aps |
Anti-CRISPR polynucleotides and polypeptides and methods of use
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
WO2018201086A1
(en)
|
2017-04-28 |
2018-11-01 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
US20200239529A1
(en)
|
2017-05-05 |
2020-07-30 |
Universitat Autònoma De Barcelona |
Nanostructured proteins and uses thereof
|
KR20180123445A
(ko)
*
|
2017-05-08 |
2018-11-16 |
주식회사 툴젠 |
인위적으로 조작된 조작면역세포
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
EP3621981A2
(en)
|
2017-05-12 |
2020-03-18 |
CRISPR Therapeutics AG |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
WO2018213351A1
(en)
*
|
2017-05-16 |
2018-11-22 |
The Regents Of The University Of California |
Thermostable rna-guided endonucleases and methods of use thereof
|
JP2020519665A
(ja)
|
2017-05-17 |
2020-07-02 |
アンセルム(アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル) |
オピオイドによる痛みの処置を改善する為のflt3阻害剤
|
US11439692B2
(en)
|
2017-05-17 |
2022-09-13 |
Modalis Therapeutics Corporation |
Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system
|
CA3064000A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Methods and compositions for cellular immunotherapy
|
CN111093714A
(zh)
|
2017-05-25 |
2020-05-01 |
通用医疗公司 |
使用分割型脱氨酶限制不需要的脱靶碱基编辑器脱氨
|
WO2018218135A1
(en)
|
2017-05-25 |
2018-11-29 |
The Children's Medical Center Corporation |
Bcl11a guide delivery
|
CN108977442B
(zh)
*
|
2017-06-05 |
2023-01-06 |
广州市锐博生物科技有限公司 |
用于dna编辑的***及其应用
|
MX2019014661A
(es)
|
2017-06-05 |
2020-07-29 |
Regeneron Pharma |
Variantes de b4galt1 y usos de estas.
|
JP7227162B2
(ja)
|
2017-06-06 |
2023-02-21 |
ザイマージェン インコーポレイテッド |
真菌株を改良するためのhtpゲノム操作プラットフォーム
|
WO2018226880A1
(en)
|
2017-06-06 |
2018-12-13 |
Zymergen Inc. |
A htp genomic engineering platform for improving escherichia coli
|
EP3634582A1
(en)
|
2017-06-08 |
2020-04-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating hyperpigmentation disorders
|
WO2018227210A1
(en)
|
2017-06-09 |
2018-12-13 |
The Regents Of The University Of California |
High-efficiency encapsulation in droplets based on hydrodynamic vortices control
|
US11517901B2
(en)
|
2017-06-09 |
2022-12-06 |
The Regents Of The University Of California |
High-efficiency particle encapsulation in droplets with particle spacing and downstream droplet sorting
|
AU2018279829B2
(en)
|
2017-06-09 |
2024-01-04 |
Editas Medicine, Inc. |
Engineered Cas9 nucleases
|
JP2020524993A
(ja)
|
2017-06-13 |
2020-08-27 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
クロンを含む組成物及びその使用
|
US20200362355A1
(en)
|
2017-06-15 |
2020-11-19 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
KR102558931B1
(ko)
|
2017-06-23 |
2023-07-21 |
인스크립타 인코포레이티드 |
핵산 가이드 뉴클레아제
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
JP2020525049A
(ja)
|
2017-06-25 |
2020-08-27 |
エスエヌアイピーアール・テクノロジーズ・リミテッドSnipr Technologies Limited |
微生物集団の変更及び細菌叢の改変
|
US11696572B2
(en)
|
2017-06-27 |
2023-07-11 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ASGR1 locus
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
CN111032863A
(zh)
|
2017-06-30 |
2020-04-17 |
科德克希思公司 |
T7 rna聚合酶变体
|
US10392616B2
(en)
|
2017-06-30 |
2019-08-27 |
Arbor Biotechnologies, Inc. |
CRISPR RNA targeting enzymes and systems and uses thereof
|
EP3645721A1
(en)
|
2017-06-30 |
2020-05-06 |
Novartis AG |
Methods for the treatment of disease with gene editing systems
|
CN111417724A
(zh)
|
2017-06-30 |
2020-07-14 |
科德克希思公司 |
T7 rna聚合酶变体
|
HRP20220615T1
(hr)
|
2017-06-30 |
2022-06-24 |
Inscripta, Inc. |
Postupci, moduli, instrumenti i sustavi za automatiziranu obradu stanica
|
SG11202000167SA
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx Inc |
Incorporation of unnatural nucleotides and methods thereof
|
EP3427756A1
(en)
|
2017-07-14 |
2019-01-16 |
Universidad Autónoma De Barcelona (UAB) |
Therapeutic nanoconjugates and uses thereof
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
WO2019036140A1
(en)
|
2017-07-17 |
2019-02-21 |
Zymergen Inc. |
METALLO-ORGANIC STRESS MATERIALS
|
US20190316101A1
(en)
|
2017-07-18 |
2019-10-17 |
Howard Hughes Medical Institute |
Methods and compositions for genetically manipulating genes and cells
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
CN109295054B
(zh)
*
|
2017-07-25 |
2024-02-06 |
广州普世利华科技有限公司 |
用于靶向病原体基因RNA的gRNA及基于C2c2的病原体基因的检测方法及试剂盒
|
EP3658173A1
(en)
|
2017-07-25 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
KR20200036912A
(ko)
|
2017-07-31 |
2020-04-07 |
리플렉션 바이오테크놀러지스 리미티드 |
안과 질환을 위한 세포 모델 및 치료요법
|
KR20200032693A
(ko)
|
2017-07-31 |
2020-03-26 |
리제너론 파마슈티칼스 인코포레이티드 |
Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
|
KR20200033259A
(ko)
|
2017-07-31 |
2020-03-27 |
리제너론 파마슈티칼스 인코포레이티드 |
생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
|
CN110891419A
(zh)
|
2017-07-31 |
2020-03-17 |
瑞泽恩制药公司 |
评价crispr/cas-诱导的与外源供体核酸的体内重组
|
WO2019024081A1
(zh)
|
2017-08-04 |
2019-02-07 |
北京大学 |
特异性识别甲基化修饰dna碱基的tale rvd及其应用
|
US11624077B2
(en)
|
2017-08-08 |
2023-04-11 |
Peking University |
Gene knockout method
|
EP3950957A1
(en)
|
2017-08-08 |
2022-02-09 |
Depixus |
In vitro isolation and enrichment of nucleic acids using site-specific nucleases
|
CN111373040A
(zh)
|
2017-08-09 |
2020-07-03 |
本森希尔股份有限公司 |
修饰基因组的组合物和方法
|
US20200260698A1
(en)
*
|
2017-08-18 |
2020-08-20 |
The Board Of Regents Of The University Of Texas System |
Exon deletion correction of duchenne muscular dystrophy mutations in the dystrophin actin binding domain 1 using crispr genome editing
|
EP3673054A4
(en)
*
|
2017-08-22 |
2021-06-02 |
Napigen, Inc. |
MODIFICATION OF THE GENOME OF ORGANITES USING POLYNUCLEOTID-GUIDED ENDONUCLEASE
|
JP2020532967A
(ja)
*
|
2017-08-23 |
2020-11-19 |
ザ ジェネラル ホスピタル コーポレイション |
変更されたPAM特異性を有する遺伝子操作されたCRISPR−Cas9ヌクレアーゼ
|
US10738327B2
(en)
|
2017-08-28 |
2020-08-11 |
Inscripta, Inc. |
Electroporation cuvettes for automation
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
EP3678680A4
(en)
*
|
2017-09-05 |
2021-12-01 |
Regeneron Pharmaceuticals, Inc. |
ADMINISTRATION OF A GENE EDITING SYSTEM CONTAINING A SINGLE RETROVIRAL PARTICLE AND METHODS OF GENERATION AND USE
|
EP3679072A1
(en)
|
2017-09-06 |
2020-07-15 |
Fred Hutchinson Cancer Research Center |
Strep-tag specific chimeric receptors and uses thereof
|
IL272940B1
(en)
|
2017-09-06 |
2024-02-01 |
Regeneron Pharma |
Variants linked to the interleukin-1 immunoglobulin-single receptor and their uses
|
WO2019051135A1
(en)
|
2017-09-06 |
2019-03-14 |
Fred Hutchinson Cancer Research Center |
METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
|
JP2020536500A
(ja)
|
2017-09-07 |
2020-12-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
溶質キャリアファミリー14メンバー1(slc14a1)の変異型及びその使用
|
US11649442B2
(en)
|
2017-09-08 |
2023-05-16 |
The Regents Of The University Of California |
RNA-guided endonuclease fusion polypeptides and methods of use thereof
|
CN111225975A
(zh)
*
|
2017-09-11 |
2020-06-02 |
加利福尼亚大学董事会 |
抗体介导的cas9向哺乳动物细胞的递送
|
CN110168093B
(zh)
*
|
2017-09-12 |
2023-08-15 |
中科蓝华(广州)生物医药技术有限公司 |
一种转染细胞内寄生虫的试剂盒及其应用
|
WO2019055862A1
(en)
|
2017-09-14 |
2019-03-21 |
Fred Hutchinson Cancer Research Center |
HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF
|
BR112020004268A2
(pt)
|
2017-09-18 |
2020-09-29 |
Futuragene Israel Ltd. |
construto, célula hospedeira, tecido vegetal, método para produzir uma planta, planta transgênica, método para engenheirar uma planta, planta, e, célula vegetal
|
TW201920661A
(zh)
|
2017-09-18 |
2019-06-01 |
大陸商博雅輯因(北京)生物科技有限公司 |
一種基因編輯t細胞及其用途
|
KR20200044982A
(ko)
|
2017-09-19 |
2020-04-29 |
어드박시스, 인크. |
박테리아 또는 리스테리아 균주의 동결건조를 위한 조성물 및 방법
|
US11453865B2
(en)
*
|
2017-09-19 |
2022-09-27 |
Massachusetts Institute Of Technology |
Applications of engineered Streptococcus canis Cas9 variants on single-base PAM targets
|
WO2019060469A2
(en)
*
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
CAS9 STREPTOCOCCUS CANIS AS A GENOMIC ENGINEERING PLATFORM WITH NEW PAM SPECIFICITY
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
IT201700105372A1
(it)
*
|
2017-09-20 |
2019-03-20 |
Fondazione St Italiano Tecnologia |
Molecola di acido nucleico funzionale e relativo uso
|
CA3076547A1
(en)
|
2017-09-20 |
2019-03-28 |
The University Of British Columbia |
Novel anti-hla-a2 antibodies and uses thereof
|
CN111655340A
(zh)
|
2017-09-20 |
2020-09-11 |
国家医疗保健研究所 |
用于调节自噬的方法和药物组合物
|
US11572574B2
(en)
*
|
2017-09-28 |
2023-02-07 |
Toolgen Incorporated |
Artificial genome manipulation for gene expression regulation
|
US11845951B2
(en)
*
|
2017-09-29 |
2023-12-19 |
Toolgen Incorporated |
Gene manipulation for treatment of retinal dysfunction disorder
|
WO2019067910A1
(en)
*
|
2017-09-29 |
2019-04-04 |
Intellia Therapeutics, Inc. |
POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION
|
AU2018338790B2
(en)
|
2017-09-29 |
2022-09-15 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized TTR locus and methods of use
|
EP3687621A4
(en)
|
2017-09-30 |
2021-08-11 |
Inscripta, Inc. |
CONTINUOUS FLOW ELECTROPORATION INSTRUMENTATION
|
EP3691656A1
(en)
|
2017-10-06 |
2020-08-12 |
Camp4 Therapeutics Corporation |
Methods and compositions for treating urea cycle disorders, in particular otc deficiency
|
US10961583B2
(en)
|
2017-10-11 |
2021-03-30 |
Regeneron Phramaceuticals, Inc. |
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
|
WO2019075197A1
(en)
|
2017-10-11 |
2019-04-18 |
The General Hospital Corporation |
METHODS OF DETECTION OF INDIVIDUAL SITE-SPECIFIC PARASITE GENOMIC DEAMINATION BY BASE EDITING TECHNOLOGIES
|
WO2019075409A1
(en)
|
2017-10-12 |
2019-04-18 |
The Regents Of The University Of California |
ISOLATION AND IDENTIFICATION WITHOUT MICROFLUIDIC LABEL OF CELLS USING FLUORESCENCE LIFE IMAGING (FLIM)
|
EP3697906A1
(en)
|
2017-10-16 |
2020-08-26 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
SG11202002822XA
(en)
|
2017-10-16 |
2020-04-29 |
Regeneron Pharma |
Cornulin (crnn) variants and uses thereof
|
CA3079172A1
(en)
|
2017-10-17 |
2019-04-25 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing for hemophilia a
|
EP3697435A1
(en)
|
2017-10-20 |
2020-08-26 |
Fred Hutchinson Cancer Research Center |
Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
|
US11499127B2
(en)
|
2017-10-20 |
2022-11-15 |
The Regents Of The University Of California |
Multi-layered microfluidic systems for in vitro large-scale perfused capillary networks
|
WO2019079787A1
(en)
*
|
2017-10-20 |
2019-04-25 |
The Regents Of The University Of California |
MICROFLUIDIC SYSTEMS AND METHODS FOR CELL TRANSFECTION VIA LIPOFLEX
|
US11690856B2
(en)
|
2017-10-23 |
2023-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Compounds for treating CMV related diseases
|
WO2019135816A2
(en)
*
|
2017-10-23 |
2019-07-11 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
KR102013798B1
(ko)
|
2017-10-25 |
2019-08-23 |
성균관대학교산학협력단 |
노화 모델 제조 방법 및 이에 의해 제조된 세포 또는 동물 노화 모델
|
EP3701029A1
(en)
|
2017-10-26 |
2020-09-02 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
CN109722415B
(zh)
|
2017-10-27 |
2021-01-26 |
博雅辑因(北京)生物科技有限公司 |
一种造血干细胞的培养组合物、培养基以及造血干细胞的培养方法
|
KR20230034416A
(ko)
|
2017-10-27 |
2023-03-09 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
내인성 t 세포 수용체의 표적화된 대체
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
EP3704245A1
(en)
|
2017-11-01 |
2020-09-09 |
Novartis AG |
Synthetic rnas and methods of use
|
RU2020117711A
(ru)
|
2017-11-01 |
2021-12-02 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ CasZ
|
US20200291395A1
(en)
*
|
2017-11-02 |
2020-09-17 |
Arbor Biotechnologies, Inc. |
Novel crispr-associated transposon systems and components
|
MA50578A
(fr)
|
2017-11-09 |
2021-09-15 |
Vertex Pharma |
Systèmes crispr/cas pour le traitement de dmd
|
EP3707150A1
(en)
|
2017-11-10 |
2020-09-16 |
Massachusetts Institute Of Technology |
Microbial production of pure single stranded nucleic acids
|
CA3076371C
(en)
|
2017-11-10 |
2022-11-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising slc30a8 mutation and methods of use
|
CN111511908A
(zh)
*
|
2017-11-10 |
2020-08-07 |
诺维信公司 |
温度敏感性cas9蛋白
|
WO2019099943A1
(en)
|
2017-11-16 |
2019-05-23 |
Astrazeneca Ab |
Compositions and methods for improving the efficacy of cas9-based knock-in strategies
|
EP3713644A1
(en)
|
2017-11-20 |
2020-09-30 |
University of Georgia Research Foundation, Inc. |
Compositions and methods for modulating hif-2& x391; to improve muscle generation and repair
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
AU2018375796A1
(en)
|
2017-11-30 |
2020-04-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized TRKB locus
|
US20220267403A1
(en)
|
2017-12-01 |
2022-08-25 |
Fred Hutchinson Cancer Research Center |
Binding proteins specific for 5t4 and uses thereof
|
US20200384033A1
(en)
|
2017-12-05 |
2020-12-10 |
Vertex Pharmaceuticals Incorporated |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
EP3720453A1
(en)
|
2017-12-05 |
2020-10-14 |
Caribou Biosciences, Inc. |
Modified lymphocytes
|
MX2020005875A
(es)
*
|
2017-12-05 |
2020-10-08 |
Bioplx Inc |
Métodos y composiciones para prevenir la infección microbiana.
|
CA3084263A1
(en)
|
2017-12-07 |
2019-06-13 |
Zymergen Inc. |
Engineered biosynthetic pathways for production of (6e)-8-hydroxygeraniol by fermentation
|
EP3720869A4
(en)
|
2017-12-08 |
2021-11-24 |
Synthetic Genomics, Inc. |
IMPROVEMENT OF ALGAE LIPID PRODUCTIVITY BY GENETIC MODIFICATION OF A PROTEIN CONTAINING A TPR DOMAIN
|
US11661599B1
(en)
|
2017-12-14 |
2023-05-30 |
National Technology & Engineering Solutions Of Sandia, Llc |
CRISPR-Cas based system for targeting single-stranded sequences
|
CN111801417A
(zh)
*
|
2017-12-14 |
2020-10-20 |
克里斯珀医疗股份公司 |
新的rna-可编程的内切核酸酶***及其在基因组编辑和其他应用中的用途
|
MX2020006150A
(es)
|
2017-12-15 |
2020-11-11 |
Flagship Pioneering Innovations Vi Llc |
Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
|
EP3707253A1
(en)
|
2017-12-15 |
2020-09-16 |
Danisco US Inc. |
Cas9 variants and methods of use
|
CA3084632A1
(en)
|
2017-12-21 |
2019-06-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of usher syndrome type 2a
|
CA3087234A1
(en)
*
|
2017-12-29 |
2019-07-04 |
The Scripps Research Institute |
Unnatural base pair compositions and methods of use
|
AU2018395264B2
(en)
|
2017-12-29 |
2023-06-22 |
Synthetic Genomics, Inc. |
Genetic modulation of photosynthetic organisms for improved growth
|
US20190201548A1
(en)
|
2017-12-29 |
2019-07-04 |
Rubius Therapeutics, Inc. |
Gene editing and targeted transcriptional modulation for engineering erythroid cells
|
EP3735590A1
(en)
|
2018-01-04 |
2020-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
WO2019136216A1
(en)
|
2018-01-05 |
2019-07-11 |
The Board Of Regents Of The University Of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
US11359208B2
(en)
|
2018-01-09 |
2022-06-14 |
Cibus Us Llc |
Shatterproof genes and mutations
|
WO2019140278A1
(en)
|
2018-01-11 |
2019-07-18 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting core binding factor antigens
|
US11268092B2
(en)
|
2018-01-12 |
2022-03-08 |
GenEdit, Inc. |
Structure-engineered guide RNA
|
BR112020014168A2
(pt)
|
2018-01-12 |
2020-12-08 |
Basf Se |
Proteína, ácido nucleico isolado, gene recombinante, vetor, célula hospedeira, planta, parte de planta ou semente de trigo, métodos para produzir, produto de trigo, farinha, farelo integral, amido, grânulos de amido ou farelo de trigo e métodos para identificar e/ou selecionar uma planta de trigo
|
CA3088180A1
(en)
|
2018-01-12 |
2019-07-18 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting transferrin
|
US20210060028A1
(en)
*
|
2018-01-17 |
2021-03-04 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
JP2021510594A
(ja)
|
2018-01-25 |
2021-04-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
臓器の虚血再灌流傷害を予防する方法における使用のためのil−33のアンタゴニスト
|
WO2019147275A1
(en)
*
|
2018-01-26 |
2019-08-01 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
US20210047632A1
(en)
*
|
2018-01-26 |
2021-02-18 |
The Children's Medical Center Corporation |
Targeting bcl11a distal regulatory elements with a cas9-cas9 fusion for fetal hemoglobin reinduction
|
US11926835B1
(en)
|
2018-01-29 |
2024-03-12 |
Inari Agriculture Technology, Inc. |
Methods for efficient tomato genome editing
|
CN111836893A
(zh)
|
2018-01-31 |
2020-10-27 |
德克萨斯大学***董事会 |
用于校正人心肌细胞中肌养蛋白突变的组合物和方法
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
US11566236B2
(en)
|
2018-02-05 |
2023-01-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
US20210093679A1
(en)
|
2018-02-05 |
2021-04-01 |
Novome Biotechnologies, Inc. |
Engineered gut microbes and uses thereof
|
MA51788A
(fr)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
Substances et méthodes pour traiter des hémoglobinopathies
|
CA3087715A1
(en)
|
2018-02-08 |
2019-08-15 |
Zymergen Inc. |
Genome editing using crispr in corynebacterium
|
KR20230022258A
(ko)
*
|
2018-02-15 |
2023-02-14 |
시그마-알드리치 컴퍼니., 엘엘씨 |
진핵 게놈 변형을 위한 조작된 cas9 시스템
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
CA3091311A1
(en)
|
2018-02-16 |
2019-08-22 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Use of antagonists of cxcr3b for treating vitiligo
|
US11718849B2
(en)
|
2018-02-19 |
2023-08-08 |
Agilent Technologies, Inc. |
Phosphopeptide-encoding oligonucleotide libraries and methods for detecting phosphorylation-dependent molecular interactions
|
KR20200124702A
(ko)
*
|
2018-02-23 |
2020-11-03 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
신규한 cas9 오르소로그
|
EP3759130A1
(en)
|
2018-02-26 |
2021-01-06 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for cellular immunotherapy
|
US11713472B2
(en)
|
2018-03-06 |
2023-08-01 |
The Board Of Trustees Of The University Of Illinois |
Genome editing in Archaea
|
EP3762719A1
(en)
|
2018-03-09 |
2021-01-13 |
Advaxis, Inc. |
Compositions and methods for evaluating attenuation and infectivity of listeria strains
|
US20190284553A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
WO2019183150A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Casebia Therapeutics Limited Liability Partnership |
Novel rna-programmable endonuclease systems and uses thereof
|
CN116349651A
(zh)
*
|
2018-03-19 |
2023-06-30 |
瑞泽恩制药公司 |
使用crispr/cas***对动物进行转录调制
|
CN111936628A
(zh)
|
2018-03-20 |
2020-11-13 |
清华大学 |
阿尔茨海默病动物模型及其应用
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
CN111148833B
(zh)
|
2018-03-26 |
2021-04-02 |
国立大学法人神户大学 |
改变细胞具有的双链dna的目标部位的方法
|
KR20210010853A
(ko)
*
|
2018-03-27 |
2021-01-28 |
(주)지플러스생명과학 |
서열 특이적인 생체내 세포 표적화
|
US10435662B1
(en)
|
2018-03-29 |
2019-10-08 |
Inscripta, Inc. |
Automated control of cell growth rates for induction and transformation
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
EP3772928A4
(en)
|
2018-04-06 |
2021-12-29 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
BR112020020919A2
(pt)
|
2018-04-13 |
2021-04-06 |
Sangamo Therapeutics France |
Receptor de antígeno quimérico específico para receptor de interleucina-23
|
US10376889B1
(en)
|
2018-04-13 |
2019-08-13 |
Inscripta, Inc. |
Automated cell processing instruments comprising reagent cartridges
|
CN112313241A
(zh)
|
2018-04-17 |
2021-02-02 |
总医院公司 |
核酸结合、修饰、和切割试剂的底物偏好和位点的灵敏体外试验
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
WO2019204766A1
(en)
|
2018-04-19 |
2019-10-24 |
The Regents Of The University Of California |
Compositions and methods for gene editing
|
WO2019209926A1
(en)
|
2018-04-24 |
2019-10-31 |
Inscripta, Inc. |
Automated instrumentation for production of peptide libraries
|
US10557216B2
(en)
|
2018-04-24 |
2020-02-11 |
Inscripta, Inc. |
Automated instrumentation for production of T-cell receptor peptide libraries
|
US10858761B2
(en)
|
2018-04-24 |
2020-12-08 |
Inscripta, Inc. |
Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
US20210239681A1
(en)
|
2018-04-27 |
2021-08-05 |
Advaxis, Inc. |
Compositions and methods for evaluating potency of listeria-based immunotherapeutics
|
WO2019213910A1
(en)
*
|
2018-05-10 |
2019-11-14 |
Syngenta Participations Ag |
Methods and compositions for targeted editing of polynucleotides
|
AU2019265916A1
(en)
|
2018-05-10 |
2020-12-10 |
Auxolytic Ltd |
Gene therapy methods and compositions using auxotrophic regulatable cells
|
EP3790607B1
(en)
|
2018-05-11 |
2023-12-27 |
Lupagen, Inc. |
Systems for closed loop, real-time modifications of patient cells
|
KR20210045360A
(ko)
|
2018-05-16 |
2021-04-26 |
신테고 코포레이션 |
가이드 rna 설계 및 사용을 위한 방법 및 시스템
|
US11946049B2
(en)
|
2018-05-22 |
2024-04-02 |
The Regents Of The University Of California |
tRNA/pre-miRNA compositions and use in treating cancer
|
EP3572512A1
(en)
|
2018-05-24 |
2019-11-27 |
B.R.A.I.N. Ag |
A method for engineering a protein
|
US11866719B1
(en)
|
2018-06-04 |
2024-01-09 |
Inari Agriculture Technology, Inc. |
Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants
|
CA3102840A1
(en)
*
|
2018-06-05 |
2019-12-12 |
Lifeedit, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2019236893A2
(en)
*
|
2018-06-07 |
2019-12-12 |
Allen Institute |
Stem cell lines containing endogenous, differentially-expressed tagged proteins, methods of production, and use thereof
|
FR3082208A1
(fr)
|
2018-06-11 |
2019-12-13 |
Fondation Mediterranee Infection |
Methode de modification d'une sequence cible d'acide nucleique d'une cellule hote
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
WO2019246488A1
(en)
|
2018-06-21 |
2019-12-26 |
Duke University |
Compositions and methods for the production of pyruvic acid and related products using dynamic metabolic control
|
EP3814369A1
(en)
|
2018-06-29 |
2021-05-05 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Tweak-receptor agonists for use in combination with immunotherapy of a cancer
|
CA3108767A1
(en)
|
2018-06-30 |
2020-01-02 |
Inscripta, Inc. |
Instruments, modules, and methods for improved detection of edited sequences in live cells
|
EP3821012A4
(en)
|
2018-07-13 |
2022-04-20 |
The Regents of The University of California |
RETROTRANSPOSON-BASED DELIVERY VEHICLE AND METHOD OF USE THEREOF
|
WO2020018964A1
(en)
|
2018-07-20 |
2020-01-23 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for controlled expression of antigen-specific receptors
|
EP3827084A4
(en)
*
|
2018-07-24 |
2023-03-15 |
Flagship Pioneering Innovations VI, LLC |
COMPOSITIONS WITH CIRCULAR POLYRIBONUCLEOTIDS AND USES THEREOF
|
WO2020028729A1
(en)
|
2018-08-01 |
2020-02-06 |
Mammoth Biosciences, Inc. |
Programmable nuclease compositions and methods of use thereof
|
US11939593B2
(en)
|
2018-08-01 |
2024-03-26 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for improving embryo development
|
JP2021533742A
(ja)
|
2018-08-07 |
2021-12-09 |
株式会社モダリス |
新規転写アクチベーター
|
CN112888481A
(zh)
|
2018-08-10 |
2021-06-01 |
桑格摩生物治疗法国公司 |
包含tnfr2结构域的新型car构建体
|
US10752874B2
(en)
|
2018-08-14 |
2020-08-25 |
Inscripta, Inc. |
Instruments, modules, and methods for improved detection of edited sequences in live cells
|
US11142740B2
(en)
|
2018-08-14 |
2021-10-12 |
Inscripta, Inc. |
Detection of nuclease edited sequences in automated modules and instruments
|
US10532324B1
(en)
|
2018-08-14 |
2020-01-14 |
Inscripta, Inc. |
Instruments, modules, and methods for improved detection of edited sequences in live cells
|
CA3107002A1
(en)
|
2018-08-15 |
2020-04-30 |
Zymergen Inc. |
Applications of crispri in high throughput metabolic engineering
|
KR20210049119A
(ko)
|
2018-08-22 |
2021-05-04 |
프레드 헛친슨 켄서 리서치 센터 |
Kras 또는 her2 항원을 표적으로 하는 면역요법
|
CN112867792A
(zh)
|
2018-08-23 |
2021-05-28 |
桑格摩生物治疗股份有限公司 |
工程化靶特异性碱基编辑器
|
AU2019329984A1
(en)
|
2018-08-28 |
2021-03-11 |
Fred Hutchinson Cancer Center |
Methods and compositions for adoptive T cell therapy incorporating induced notch signaling
|
BR112021003670A2
(pt)
|
2018-08-28 |
2021-05-18 |
Vor Biopharma, Inc. |
células-tronco hematopoéticas geneticamente modificadas e seus usos
|
US11965154B2
(en)
|
2018-08-30 |
2024-04-23 |
Inscripta, Inc. |
Detection of nuclease edited sequences in automated modules and instruments
|
US11479762B1
(en)
|
2018-08-31 |
2022-10-25 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
SG11202101984PA
(en)
|
2018-08-31 |
2021-03-30 |
Univ Yale |
Compositions and methods for enhancing triplex and nuclease-based gene editing
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
JP7444858B2
(ja)
|
2018-09-05 |
2024-03-06 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
喘息及びアレルギー性疾患を処置するための方法及び組成物
|
EP3847251A1
(en)
|
2018-09-07 |
2021-07-14 |
Astrazeneca AB |
Compositions and methods for improved nucleases
|
US20200080107A1
(en)
|
2018-09-07 |
2020-03-12 |
Crispr Therapeutics Ag |
Universal donor cells
|
WO2020053125A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
CN112969367B
(zh)
|
2018-09-13 |
2023-04-07 |
瑞泽恩制药公司 |
作为c3肾小球病模型的补体因子h基因敲除大鼠
|
JP2022501374A
(ja)
|
2018-09-21 |
2022-01-06 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
糖尿病を治療するための方法及び組成物、ならびに分泌タンパク質をコードするmRNAを濃縮する方法
|
WO2020068702A1
(en)
|
2018-09-24 |
2020-04-02 |
Fred Hutchinson Cancer Research Center |
Chimeric receptor proteins and uses thereof
|
WO2020064702A1
(en)
|
2018-09-25 |
2020-04-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
GB201815820D0
(en)
|
2018-09-28 |
2018-11-14 |
Univ Wageningen |
Off-target activity inhibitors for guided endonucleases
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
WO2020071528A1
(ja)
|
2018-10-04 |
2020-04-09 |
株式会社カネカ |
植物のゲノム編集に用いられるdna構築物
|
US20210347898A1
(en)
|
2018-10-09 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
|
US11851663B2
(en)
|
2018-10-14 |
2023-12-26 |
Snipr Biome Aps |
Single-vector type I vectors
|
CA3116452A1
(en)
|
2018-10-15 |
2020-04-23 |
Fondazione Telethon |
Genome editing methods and constructs
|
WO2020081173A1
(en)
|
2018-10-16 |
2020-04-23 |
Pioneer Hi-Bred International, Inc. |
Genome edited fine mapping and causal gene identification
|
WO2020081843A1
(en)
|
2018-10-17 |
2020-04-23 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for delivering transgenes
|
WO2020082047A1
(en)
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiencey
|
MX2021004282A
(es)
|
2018-10-18 |
2021-09-08 |
Intellia Therapeutics Inc |
Construcciones de ácido nucleico y métodos de uso.
|
WO2020079162A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for inducing full ablation of hematopoiesis
|
SG11202103734PA
(en)
|
2018-10-18 |
2021-05-28 |
Intellia Therapeutics Inc |
Compositions and methods for expressing factor ix
|
BR112021007343A2
(pt)
|
2018-10-18 |
2021-08-03 |
Intellia Therapeutics, Inc. |
composições e métodos para expressão de transgene a partir de um lócus de albumina
|
US11214781B2
(en)
|
2018-10-22 |
2022-01-04 |
Inscripta, Inc. |
Engineered enzyme
|
CA3115534A1
(en)
|
2018-10-22 |
2020-04-30 |
Inscripta, Inc. |
Engineered nucleic acid-guided nucleases
|
US11946047B2
(en)
*
|
2018-10-23 |
2024-04-02 |
Texas Tech University System |
Treatment strategies against anthrax by interfering with critical host factors
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
US20210388389A1
(en)
|
2018-10-30 |
2021-12-16 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
US11066663B2
(en)
|
2018-10-31 |
2021-07-20 |
Zymergen Inc. |
Multiplexed deterministic assembly of DNA libraries
|
WO2020089448A1
(en)
|
2018-11-01 |
2020-05-07 |
Keygene N.V. |
Dual guide rna for crispr/cas genome editing in plants cells
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
AU2019377553A1
(en)
|
2018-11-09 |
2021-05-27 |
Fred Hutchinson Cancer Center |
T cell receptors specific for mesothelin and their use in immunotherapy
|
KR20210093954A
(ko)
|
2018-11-16 |
2021-07-28 |
아스텔라스세이야쿠 가부시키가이샤 |
유트로핀 유전자를 표적으로 하여 근이영양증을 치료하는 방법
|
US20220033879A1
(en)
|
2018-11-28 |
2022-02-03 |
Keygene N.V. |
Targeted enrichment by endonuclease protection
|
JP2022513159A
(ja)
*
|
2018-11-29 |
2022-02-07 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
Rnaを調節する方法
|
WO2020112195A1
(en)
|
2018-11-30 |
2020-06-04 |
Yale University |
Compositions, technologies and methods of using plerixafor to enhance gene editing
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
CN113423823A
(zh)
*
|
2018-12-12 |
2021-09-21 |
国立大学法人九州大学 |
经基因组编辑的细胞的制造方法
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
KR20210104068A
(ko)
|
2018-12-14 |
2021-08-24 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
게놈 편집을 위한 신규한 crispr-cas 시스템
|
AU2019406778A1
(en)
*
|
2018-12-17 |
2021-07-22 |
Massachusetts Institute Of Technology |
Crispr-associated transposase systems and methods of use thereof
|
US20220062340A1
(en)
|
2018-12-19 |
2022-03-03 |
King's College London |
Immunotherapeutic methods and compositions
|
MX2021007400A
(es)
|
2018-12-20 |
2021-07-15 |
Regeneron Pharma |
Expansion de repeticiones mediada por nucleasas.
|
US20220143136A1
(en)
|
2018-12-21 |
2022-05-12 |
Northwestern University |
Use of annexins in preventing and treating muscle membrane injury
|
JP2022516445A
(ja)
*
|
2018-12-24 |
2022-02-28 |
ビステラ, インコーポレイテッド |
エピトープおよびパラトープを同定する方法
|
WO2020136216A1
(en)
|
2018-12-27 |
2020-07-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of identifying subjects having or at risk of having a coagulation related disorder
|
US20220145296A1
(en)
|
2018-12-27 |
2022-05-12 |
LifeEDIT Therapeutics, Inc. |
Polypeptides useful for gene editing and methods of use
|
WO2020142153A1
(en)
*
|
2018-12-31 |
2020-07-09 |
Htg Molecular Diagnostics, Inc. |
Methods of detecting dna and rna in the same sample
|
BR112021013157A8
(pt)
|
2019-01-03 |
2022-12-06 |
Inst Nat Sante Rech Med |
Usos de um inibidor de nrp-1, uso de uma combinação, uso de um anticorpo multiespecífico, método ex vivo para predizer, uso de um inibidor, anticorpo multiespecífico, população de células modificadas, método ex vivo de produção e uso de uma população de células t
|
EP3931313A2
(en)
|
2019-01-04 |
2022-01-05 |
Mammoth Biosciences, Inc. |
Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
|
TW202043256A
(zh)
*
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
***新抗原及其用途
|
WO2020148206A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
WO2020150144A1
(en)
|
2019-01-15 |
2020-07-23 |
Seminis Vegetable Seeds, Inc. |
Green bean plants with improved disease resistance
|
US20220119516A1
(en)
|
2019-01-16 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Variants of erythroferrone and their use
|
WO2020148398A1
(en)
|
2019-01-17 |
2020-07-23 |
Universitat Autonoma De Barcelona (Uab) |
Therapeutic nanoconjugates and uses thereof
|
WO2020154595A1
(en)
|
2019-01-24 |
2020-07-30 |
Massachusetts Institute Of Technology |
Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
|
WO2020160125A1
(en)
*
|
2019-01-29 |
2020-08-06 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising an endonuclease and methods for purifying an endonuclease
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
US20220117911A1
(en)
|
2019-02-04 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
US20220145330A1
(en)
|
2019-02-10 |
2022-05-12 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Modified mitochondrion and methods of use thereof
|
JP2022520104A
(ja)
|
2019-02-15 |
2022-03-28 |
シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー |
Crispr/cas融合タンパク質およびシステム
|
MA54951A
(fr)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
GB2596461B
(en)
|
2019-02-20 |
2023-09-27 |
Fred Hutchinson Cancer Center |
Binding proteins specific for RAS neoantigens and uses thereof
|
US20220290120A1
(en)
|
2019-02-25 |
2022-09-15 |
Novome Biotechnologies, Inc. |
Plasmids for gene editing
|
US20220049273A1
(en)
*
|
2019-03-01 |
2022-02-17 |
Arbor Biotechnologies, Inc. |
Novel crispr dna targeting enzymes and systems
|
WO2020178759A1
(en)
|
2019-03-04 |
2020-09-10 |
King Abdullah University Of Science And Technology |
Compositions and methods of targeted nucleic acid enrichment by loop adapter protection and exonuclease digestion
|
WO2020181101A1
(en)
|
2019-03-07 |
2020-09-10 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
CN113728106A
(zh)
|
2019-03-08 |
2021-11-30 |
齐默尔根公司 |
微生物中的迭代基因组编辑
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
EP3938386A1
(en)
|
2019-03-11 |
2022-01-19 |
Fred Hutchinson Cancer Research Center |
High avidity wt1 t cell receptors and uses thereof
|
CA3133226A1
(en)
|
2019-03-11 |
2020-09-17 |
Sorrento Therapeutics, Inc. |
Improved process for integration of dna constructs using rna-guided endonucleases
|
EP4317950A3
(en)
|
2019-03-18 |
2024-04-17 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
|
EP3769090B1
(en)
|
2019-03-18 |
2023-11-15 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
|
DE112020001342T5
(de)
|
2019-03-19 |
2022-01-13 |
President and Fellows of Harvard College |
Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
|
EP3947691A4
(en)
|
2019-03-25 |
2022-12-14 |
Inscripta, Inc. |
SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST
|
US11001831B2
(en)
|
2019-03-25 |
2021-05-11 |
Inscripta, Inc. |
Simultaneous multiplex genome editing in yeast
|
JP2022527766A
(ja)
|
2019-03-27 |
2022-06-06 |
パイオニア ハイ-ブレッド インターナショナル, インコーポレイテッド |
植物外稙片の形質転換
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
US20220249511A1
(en)
|
2019-03-29 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
SG11202108451VA
(en)
|
2019-04-03 |
2021-09-29 |
Regeneron Pharma |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
KR102487901B1
(ko)
|
2019-04-04 |
2023-01-12 |
리제너론 파마슈티칼스 인코포레이티드 |
표적화된 변형의 표적화 벡터로의 무흔적 도입을 위한 방법
|
IL286905B1
(en)
|
2019-04-04 |
2024-02-01 |
Regeneron Pharma |
Non-human animals containing the human coagulation factor 12 locus
|
CA3136061A1
(en)
|
2019-04-05 |
2020-10-08 |
Osaka University |
Method for producing knock-in cell
|
MX2021012157A
(es)
|
2019-04-05 |
2022-01-06 |
Danisco Us Inc |
Métodos para la integración de polinucleótidos en el genoma de bacillus usando constructos de adn recombinante circular dual y composiciones de los mismos.
|
WO2020206202A1
(en)
|
2019-04-05 |
2020-10-08 |
Danisco Us Inc |
Methods for integrating a donor dna sequence into the genome of bacillus using linear recombinant dna constructs and compositions thereof
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
US20220162648A1
(en)
|
2019-04-12 |
2022-05-26 |
Astrazeneca Ab |
Compositions and methods for improved gene editing
|
GB201905360D0
(en)
|
2019-04-16 |
2019-05-29 |
Univ Nottingham |
Fungal strains, production and uses thereof
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
JP2022531347A
(ja)
|
2019-04-30 |
2022-07-06 |
エメンドバイオ・インコーポレイテッド |
新規のomni-50crisprヌクレアーゼ
|
WO2020221796A1
(en)
|
2019-04-30 |
2020-11-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020221291A1
(zh)
|
2019-04-30 |
2020-11-05 |
博雅辑因(北京)生物科技有限公司 |
一种血红蛋白病治疗有效性预测方法
|
US11692197B2
(en)
|
2019-05-06 |
2023-07-04 |
Inari Agriculture Technology, Inc. |
Delivery of biological molecules to plant cells
|
EP3966327A1
(en)
|
2019-05-08 |
2022-03-16 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas all-in-two vector systems for treatment of dmd
|
US20220220495A1
(en)
|
2019-05-10 |
2022-07-14 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
US20220228153A1
(en)
|
2019-05-23 |
2022-07-21 |
Vor Biopharma Inc. |
Compositions and methods for cd33 modification
|
WO2020239623A1
(en)
|
2019-05-24 |
2020-12-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of ngal inhibitors for the treating chronic wound
|
JP2022535413A
(ja)
|
2019-06-04 |
2022-08-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
がんの処置のためのp38アルファ-キナーゼ阻害剤と組み合わせたニューロピリンアンタゴニスト
|
WO2020245208A1
(en)
|
2019-06-04 |
2020-12-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
|
JP2022534867A
(ja)
|
2019-06-04 |
2022-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ベータスリップ変異を有するヒト化ttr遺伝子座を含む非ヒト動物と使用方法
|
US10837021B1
(en)
|
2019-06-06 |
2020-11-17 |
Inscripta, Inc. |
Curing for recursive nucleic acid-guided cell editing
|
AU2020289591A1
(en)
|
2019-06-07 |
2021-12-23 |
Scribe Therapeutics Inc. |
Engineered CasX systems
|
AU2020289581A1
(en)
|
2019-06-07 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized albumin locus
|
US11845957B2
(en)
|
2019-06-14 |
2023-12-19 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
WO2020249769A1
(en)
|
2019-06-14 |
2020-12-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating ocular diseases related to mitochondrial dna maintenance
|
US10907125B2
(en)
|
2019-06-20 |
2021-02-02 |
Inscripta, Inc. |
Flow through electroporation modules and instrumentation
|
WO2020257395A1
(en)
|
2019-06-21 |
2020-12-24 |
Inscripta, Inc. |
Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli
|
KR20220052905A
(ko)
|
2019-06-25 |
2022-04-28 |
이나리 아그리컬쳐 테크놀로지, 인크. |
개선된 상동성 의존적 수선 게놈 편집
|
US10927385B2
(en)
|
2019-06-25 |
2021-02-23 |
Inscripta, Inc. |
Increased nucleic-acid guided cell editing in yeast
|
US11905532B2
(en)
|
2019-06-25 |
2024-02-20 |
Massachusetts Institute Of Technology |
Compositions and methods for molecular memory storage and retrieval
|
CA3217237A1
(en)
|
2019-06-27 |
2020-12-30 |
Regeneration Pharmaceuticals, Inc. |
Modeling tdp-43 proteinopathy
|
WO2021001431A1
(en)
|
2019-07-02 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer
|
WO2021001427A1
(en)
|
2019-07-02 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
|
GB201909597D0
(en)
|
2019-07-03 |
2019-08-14 |
Univ Wageningen |
Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof
|
US20220249698A1
(en)
|
2019-07-12 |
2022-08-11 |
Riken |
Therapeutic agent for disease caused by dominant mutant gene
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
EP3999091A1
(en)
|
2019-07-15 |
2022-05-25 |
MedImmune Limited |
Tripartite systems for protein dimerization and methods of use
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
WO2021009299A1
(en)
|
2019-07-17 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process
|
EP4003325A1
(en)
|
2019-07-24 |
2022-06-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa
|
US20220275105A1
(en)
|
2019-08-02 |
2022-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
JP2022545385A
(ja)
*
|
2019-08-12 |
2022-10-27 |
ライフエディット セラピューティクス,インコーポレイティド |
Rna誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法
|
CN114555790A
(zh)
|
2019-08-20 |
2022-05-27 |
弗雷德哈钦森癌症研究中心 |
Wt-1特异性t细胞免疫疗法
|
KR20220047381A
(ko)
|
2019-08-28 |
2022-04-15 |
보르 바이오파마 인크. |
Cd123 변형을 위한 조성물 및 방법
|
AU2020338011A1
(en)
|
2019-08-28 |
2022-03-10 |
Vor Biopharma Inc. |
Compositions and methods for CLL1 modification
|
US20220288176A1
(en)
*
|
2019-08-28 |
2022-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Circular rna modification and methods of use
|
EP4021496A1
(en)
|
2019-08-30 |
2022-07-06 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
AU2020342207A1
(en)
|
2019-09-04 |
2022-04-21 |
Edigene (Guangzhou) Inc. |
Method for evaluating gene editing therapy based on off-target assessment
|
WO2021044012A1
(en)
|
2019-09-05 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment and pronostic of acute myeloid leukemia
|
EP4025697A1
(en)
|
2019-09-05 |
2022-07-13 |
Benson Hill, Inc. |
Compositions and methods for modifying genomes
|
JP2022547053A
(ja)
|
2019-09-05 |
2022-11-10 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
ユニバーサルドナー細胞
|
WO2021044379A1
(en)
|
2019-09-05 |
2021-03-11 |
Crispr Therapeutics Ag |
Universal donor cells
|
JP2022547564A
(ja)
*
|
2019-09-10 |
2022-11-14 |
サイエンス ソリューションズ エル・エル・シー |
新規なクラス2のii型及びv型crispr-cas rna誘導型エンドヌクレアーゼ
|
WO2021047775A1
(en)
|
2019-09-12 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of tgfb/activinb signaling pathway for the treatment of patients suffering from medulloblastoma group 3
|
BR112022004545A2
(pt)
|
2019-09-12 |
2022-05-31 |
Basf Se |
Métodos para aumentar a expressão derivada de um promotor vegetal e produzir uma planta, construção de expressão recombinante, vetor de expressão, célula ou planta transgênica, cultura de células transgênicas e usos
|
US20210079394A1
(en)
|
2019-09-13 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
WO2021061815A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4α) GENE EXPRESSION
|
CN114391040A
(zh)
|
2019-09-23 |
2022-04-22 |
欧米茄治疗公司 |
用于调节载脂蛋白b(apob)基因表达的组合物和方法
|
US11542513B2
(en)
|
2019-09-26 |
2023-01-03 |
Seminis Vegetable Seeds, Inc. |
Lettuce plants having resistance to Nasonovia ribisnigri biotype Nr:1
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
WO2021064180A1
(en)
|
2019-10-03 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
EP4038190A1
(en)
*
|
2019-10-03 |
2022-08-10 |
Artisan Development Labs, Inc. |
Crispr systems with engineered dual guide nucleic acids
|
WO2021069387A1
(en)
|
2019-10-07 |
2021-04-15 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
EP4043473A4
(en)
|
2019-10-11 |
2024-03-27 |
Sumitomo Chemical Co |
METHOD FOR PRODUCING NUCLEIC ACID OLIGOMERS
|
US20230174972A1
(en)
*
|
2019-10-15 |
2023-06-08 |
Agency For Science, Technology And Research |
Assays For Measuring Nucleic Acid Modifying Enzyme Activity
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
WO2021078359A1
(en)
|
2019-10-21 |
2021-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of cubilin for the treatment of chronic kidney diseases
|
WO2021081264A1
(en)
|
2019-10-24 |
2021-04-29 |
Pairwise Plants Services, Inc. |
Optimized crispr-cas nucleases and base editors and methods of use thereof
|
EP4051286A1
(en)
|
2019-10-29 |
2022-09-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating uveal melanoma
|
KR20220097414A
(ko)
|
2019-11-08 |
2022-07-07 |
리제너론 파마슈티칼스 인코포레이티드 |
X-연관 연소 망막층간분리 치료법을 위한 crispr 및 aav 전략
|
BR112022009137A2
(pt)
*
|
2019-11-13 |
2022-07-26 |
Crispr Therapeutics Ag |
Métodos de fabricação de células t com receptor de antígeno quimérico (car)
|
IL292329A
(en)
*
|
2019-11-13 |
2022-06-01 |
Crispr Therapeutics Ag |
Manufacturing process for preparing t cells expressing chimeric antigen receptors
|
US11203762B2
(en)
|
2019-11-19 |
2021-12-21 |
Inscripta, Inc. |
Methods for increasing observed editing in bacteria
|
US20220389459A1
(en)
|
2019-11-19 |
2022-12-08 |
Danisco Us Inc. |
Selection marker free methods for modifying the genome of bacillus and compositions thereof
|
BR112022009803A2
(pt)
|
2019-11-20 |
2022-08-16 |
Corbion Biotech Inc |
Variantes de sacarose invertase
|
CN110938659B
(zh)
*
|
2019-11-22 |
2022-05-10 |
广东省微生物研究所(广东省微生物分析检测中心) |
一种提高纤维堆囊菌埃博霉素产量的dCas9载体及其构建方法
|
WO2021099600A1
(en)
|
2019-11-22 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
CA3162892A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
CA3158729A1
(en)
|
2019-11-27 |
2021-06-03 |
Virginia Kincaid |
Multipartite luciferase peptides and polypeptides
|
EP4065224A1
(en)
|
2019-11-27 |
2022-10-05 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of neuropilin antagonists for the treatment of endometriosis
|
WO2021105191A1
(en)
|
2019-11-29 |
2021-06-03 |
Basf Se |
Increasing resistance against fungal infections in plants
|
US20230055682A1
(en)
|
2019-12-03 |
2023-02-23 |
Beam Therapeutics lnc. |
Synthetic guide rna, compositions, methods, and uses thereof
|
EP4069852A1
(en)
|
2019-12-03 |
2022-10-12 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
CN114787347A
(zh)
|
2019-12-10 |
2022-07-22 |
因思科瑞普特公司 |
新颖的mad核酸酶
|
US10704033B1
(en)
|
2019-12-13 |
2020-07-07 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
GB201918586D0
(en)
|
2019-12-17 |
2020-01-29 |
Patterson James |
Engineered platelets for targeted delivery of a therapeutic agent
|
KR20220118498A
(ko)
|
2019-12-18 |
2022-08-25 |
인스크립타 인코포레이티드 |
핵산-가이드된 뉴클레아제 편집된 세포의 생체 내 검출을 위한 캐스케이드/dcas3 상보 검정
|
CA3161898A1
(en)
|
2019-12-19 |
2021-06-24 |
Basf Se |
Increasing space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility in the production of fine chemicals
|
BR112022011895A2
(pt)
|
2019-12-20 |
2022-09-06 |
Basf Se |
Diminuição da toxidez de terpenos e aumento da produção potencial em microrganismos
|
IL271656A
(en)
|
2019-12-22 |
2021-06-30 |
Yeda Res & Dev |
System and methods for identifying cells that have undergone genome editing
|
EP3842452A1
(en)
|
2019-12-26 |
2021-06-30 |
Universitat Autònoma de Barcelona |
Scaffold proteins and therapeutic nanoconjugates based on nidogen
|
US20230054266A1
(en)
|
2019-12-30 |
2023-02-23 |
Edigene Biotechnology Inc. |
Method for purifying ucart cell and use thereof
|
US20230059884A1
(en)
|
2019-12-30 |
2023-02-23 |
Edigene Biotechnology Inc. |
Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof
|
US11859172B2
(en)
|
2020-01-02 |
2024-01-02 |
The Trustees Of Columbia University In The City Of New York |
Programmable and portable CRISPR-Cas transcriptional activation in bacteria
|
CN110982820A
(zh)
*
|
2020-01-03 |
2020-04-10 |
云南中烟工业有限责任公司 |
一种烟草单倍体的基因编辑方法
|
US10689669B1
(en)
|
2020-01-11 |
2020-06-23 |
Inscripta, Inc. |
Automated multi-module cell processing methods, instruments, and systems
|
US20230076415A1
(en)
|
2020-01-17 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2021148447A1
(en)
|
2020-01-21 |
2021-07-29 |
Limagrain Europe |
Wheat haploid inducer plant and uses
|
US20210261932A1
(en)
*
|
2020-01-24 |
2021-08-26 |
The General Hospital Corporation |
Crispr-cas enzymes with enhanced on-target activity
|
WO2021151073A2
(en)
*
|
2020-01-24 |
2021-07-29 |
The General Hospital Corporation |
Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
|
KR20220133257A
(ko)
|
2020-01-27 |
2022-10-04 |
인스크립타 인코포레이티드 |
전기천공 모듈 및 기구
|
US20210227812A1
(en)
|
2020-01-28 |
2021-07-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized pnpla3 locus and methods of use
|
JPWO2021153047A1
(lt)
|
2020-01-29 |
2021-08-05 |
|
|
CN115003680A
(zh)
|
2020-01-29 |
2022-09-02 |
住友化学株式会社 |
制备核酸寡聚物的方法
|
WO2021158883A1
(en)
|
2020-02-07 |
2021-08-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized klkb1 locus and methods of use
|
US20230357784A1
(en)
|
2020-02-21 |
2023-11-09 |
Limagrain Europe |
Prime editing technology for plant genome engineering
|
CN115485300A
(zh)
|
2020-02-26 |
2022-12-16 |
索伦托药业有限公司 |
具有通用掩蔽部分的可活化的抗原结合蛋白
|
CA3167369A1
(en)
|
2020-03-04 |
2021-09-10 |
Tara YOUNG |
Methods and compositions for sensitization of tumor cells to immune therapy
|
JP2023517326A
(ja)
|
2020-03-11 |
2023-04-25 |
オメガ セラピューティクス, インコーポレイテッド |
フォークヘッドボックスp3(foxp3)遺伝子発現をモジュレートするための組成物および方法
|
CN115484990A
(zh)
|
2020-03-12 |
2022-12-16 |
基础科学研究院 |
诱导具有基因组序列变异的细胞凋亡的组合物及使用组合物诱导细胞凋亡的方法
|
WO2021188840A1
(en)
|
2020-03-19 |
2021-09-23 |
Rewrite Therapeutics, Inc. |
Methods and compositions for directed genome editing
|
KR20230004510A
(ko)
|
2020-03-20 |
2023-01-06 |
인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) |
인간 cd45rc에 특이적인 키메라 항원 수용체 및 이의 용도
|
WO2021195079A1
(en)
|
2020-03-23 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
EP4129050A1
(en)
|
2020-03-26 |
2023-02-08 |
National Agriculture And Food Research Organization |
Method for producing temperature-sensitive male sterile plant
|
EP4130018A4
(en)
|
2020-03-27 |
2024-04-17 |
Sumitomo Chemical Co |
PROCESS FOR THE PRODUCTION OF NUCLEIC ACID OLIGOMERS
|
US20210319851A1
(en)
|
2020-04-03 |
2021-10-14 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
CN115427566A
(zh)
|
2020-04-08 |
2022-12-02 |
阿斯利康(瑞典)有限公司 |
用于改善的位点特异性修饰的组合物和方法
|
EP4132954A1
(en)
|
2020-04-08 |
2023-02-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of cdon inhibitors for the treatment of endothelial dysfunction
|
US20210332388A1
(en)
|
2020-04-24 |
2021-10-28 |
Inscripta, Inc. |
Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
|
TW202208626A
(zh)
*
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna引導核酸酶及其活性片段與變體,以及使用方法
|
WO2021217083A1
(en)
|
2020-04-24 |
2021-10-28 |
Sorrento Therapeutics, Inc. |
Memory dimeric antigen receptors
|
US20230348852A1
(en)
|
2020-04-27 |
2023-11-02 |
Novartis Ag |
Methods and compositions for ocular cell therapy
|
CA3173889A1
(en)
|
2020-05-04 |
2021-11-11 |
Saliogen Therapeutics, Inc. |
Transposition-based therapies
|
KR20230006827A
(ko)
|
2020-05-05 |
2023-01-11 |
제너스 피엘씨 |
Cd163의 표적 불활화를 통한 돼지 종의 건강 개선 방법
|
EP4146797A1
(en)
|
2020-05-06 |
2023-03-15 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート,インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
EP4150081A1
(en)
|
2020-05-13 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of betahemoglobinopathies
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
US11787841B2
(en)
|
2020-05-19 |
2023-10-17 |
Inscripta, Inc. |
Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
|
US11263022B2
(en)
*
|
2020-05-21 |
2022-03-01 |
Microsoft Technology Licensing, Llc |
Mechanism to turn on/off post-processing features in the device media foundation transform
|
EP4161552A1
(en)
|
2020-06-05 |
2023-04-12 |
The Broad Institute, Inc. |
Compositions and methods for treating neoplasia
|
EP4161583A1
(en)
|
2020-06-05 |
2023-04-12 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for treating ocular diseases
|
CN111748539B
(zh)
*
|
2020-06-11 |
2021-10-22 |
中国农业科学院农产品加工研究所 |
CRISPR/LpCas9基因编辑***及其应用
|
IL298473A
(en)
|
2020-06-11 |
2023-01-01 |
Novartis Ag |
zbtb32 inhibitors and uses thereof
|
EP4168006A1
(en)
|
2020-06-18 |
2023-04-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
New strategy for treating pancreatic cancer
|
WO2021263146A2
(en)
|
2020-06-26 |
2021-12-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ace2 locus
|
JP2023533979A
(ja)
*
|
2020-07-08 |
2023-08-07 |
ザ ジャクソン ラボラトリー |
ヒト自然免疫機能を支えるトランスジェニックマウスモデル
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
KR20230037586A
(ko)
|
2020-07-09 |
2023-03-16 |
가부시키가이샤 모달리스 |
Mapt 유전자를 표적으로 하는 알츠하이머병의 치료 방법
|
EP4179079A1
(en)
|
2020-07-10 |
2023-05-17 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
AU2021310363A1
(en)
|
2020-07-15 |
2023-03-16 |
LifeEDIT Therapeutics, Inc. |
Uracil stabilizing proteins and active fragments and variants thereof and methods of use
|
AU2021204717A1
(en)
|
2020-07-15 |
2022-02-03 |
Seminis Vegetable Seeds, Inc. |
Green Bean Plants with Improved Disease Resistance
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
US20230295615A1
(en)
|
2020-08-07 |
2023-09-21 |
The Jackson Laboratory |
Targeted Sequence Insertion Compositions and Methods
|
KR20230044537A
(ko)
|
2020-08-13 |
2023-04-04 |
예일 유니버시티 |
원하는 표현형을 갖는 car t 세포의 조작 및 선택을 위한 조성물 및 방법
|
BR112023002885A2
(pt)
|
2020-08-18 |
2023-03-21 |
Pioneer Hi Bred Int |
Genes de resistência a múltiplas doenças e seus empilhamentos genômicos
|
CA3188867A1
(en)
|
2020-08-20 |
2022-02-24 |
Xueyin Wang |
Compositions and methods for treating ceacam positive cancers
|
TW202214846A
(zh)
|
2020-08-20 |
2022-04-16 |
美商A2生物治療學股份有限公司 |
用於治療egfr陽性癌症之組合物及方法
|
WO2022040454A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
WO2022047165A1
(en)
|
2020-08-28 |
2022-03-03 |
Vor Biopharma Inc. |
Compositions and methods for cd123 modification
|
EP4204565A1
(en)
|
2020-08-28 |
2023-07-05 |
Vor Biopharma Inc. |
Compositions and methods for cll1 modification
|
US20230265214A1
(en)
|
2020-08-31 |
2023-08-24 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
BR112023003972A2
(pt)
|
2020-09-04 |
2023-04-18 |
Univ Kobe Nat Univ Corp |
Complexos de um módulo de reconhecimento de sequência de ácido nucleico ligado a uma desaminase e de um fragmento amino-terminal de um módulo de reconhecimento de sequência de ácido nucleico, uma desaminase e um fragmento carboxi-terminal de um módulo de reconhecimento de sequência de ácido nucleico ligado ao mesmo, ácido nucleico, vetor, e, método para alterar um sítio alvo de um ácido desoxirribonucleico de fita dupla de uma célula
|
IL301139A
(en)
|
2020-09-11 |
2023-05-01 |
Lifeedit Therapeutics Inc |
Enzymes from secondary DNA and active fragments and their variants and methods of use
|
WO2022056459A1
(en)
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Compositions and methods for cd5 modification
|
EP4211244A1
(en)
|
2020-09-14 |
2023-07-19 |
Vor Biopharma, Inc. |
Compositions and methods for cd38 modification
|
WO2022060749A1
(en)
|
2020-09-15 |
2022-03-24 |
Inscripta, Inc. |
Crispr editing to embed nucleic acid landing pads into genomes of live cells
|
EP4214311A2
(en)
|
2020-09-18 |
2023-07-26 |
Artisan Development Labs, Inc. |
Constructs and uses thereof for efficient and specific genome editing
|
US20240033290A1
(en)
|
2020-09-18 |
2024-02-01 |
Vor Biopharma Inc. |
Compositions and methods for cd7 modification
|
JP2023542528A
(ja)
|
2020-09-24 |
2023-10-10 |
フレッド ハッチンソン キャンサー センター |
Sox2抗原を標的とする免疫療法
|
JPWO2022064908A1
(lt)
|
2020-09-24 |
2022-03-31 |
|
|
WO2022067033A1
(en)
*
|
2020-09-24 |
2022-03-31 |
Flagship Pioneering Innovations V, Inc. |
Compositions and methods for inhibiting gene expression
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
WO2022067240A1
(en)
|
2020-09-28 |
2022-03-31 |
Vor Biopharma, Inc. |
Compositions and methods for cd6 modification
|
US10894812B1
(en)
|
2020-09-30 |
2021-01-19 |
Alpine Roads, Inc. |
Recombinant milk proteins
|
WO2022072643A1
(en)
|
2020-09-30 |
2022-04-07 |
Vor Biopharma Inc. |
Compositions and methods for cd30 gene modification
|
WO2022070107A1
(en)
|
2020-09-30 |
2022-04-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
US10947552B1
(en)
|
2020-09-30 |
2021-03-16 |
Alpine Roads, Inc. |
Recombinant fusion proteins for producing milk proteins in plants
|
AU2021353004A1
(en)
|
2020-09-30 |
2023-04-13 |
Nobell Foods, Inc. |
Recombinant milk proteins and food compositions comprising the same
|
JP2023545403A
(ja)
|
2020-10-02 |
2023-10-30 |
リマグレン、ヨーロッパ |
Crisprを介した指令コドン書換え
|
US20230375571A1
(en)
|
2020-10-05 |
2023-11-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling
|
WO2022076353A1
(en)
|
2020-10-06 |
2022-04-14 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for treating mage-a1-expressing disease
|
US20230407366A1
(en)
|
2020-10-06 |
2023-12-21 |
Keygene N.V. |
Targeted sequence addition
|
JP2023549042A
(ja)
|
2020-10-13 |
2023-11-22 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック |
接合およびcrispr/casシステムを組み合わせた標的抗菌性プラスミド並びにその使用
|
JP2023546597A
(ja)
|
2020-10-21 |
2023-11-06 |
マサチューセッツ インスティテュート オブ テクノロジー |
部位特異的標的化エレメントによるプログラム可能な付加(paste)を使用した部位特異的遺伝子操作のためのシステム、方法及び組成物
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
AU2021372482A1
(en)
|
2020-10-27 |
2023-05-25 |
Vor Biopharma Inc. |
Compositions and methods for treating hematopoietic malignancy
|
WO2022094245A1
(en)
|
2020-10-30 |
2022-05-05 |
Vor Biopharma, Inc. |
Compositions and methods for bcma modification
|
CN112553195B
(zh)
*
|
2020-11-05 |
2022-04-05 |
南方医科大学 |
一种用于CRISPR-Cas9定点突变编辑DNMT1基因的试剂及其应用
|
JPWO2022097663A1
(lt)
|
2020-11-06 |
2022-05-12 |
|
|
US11512297B2
(en)
|
2020-11-09 |
2022-11-29 |
Inscripta, Inc. |
Affinity tag for recombination protein recruitment
|
WO2022104090A1
(en)
|
2020-11-13 |
2022-05-19 |
Vor Biopharma Inc. |
Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors
|
MX2023005609A
(es)
|
2020-11-13 |
2023-05-29 |
Novartis Ag |
Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
US20240002904A1
(en)
|
2020-11-24 |
2024-01-04 |
Keygene N.V. |
Targeted enrichment using nanopore selective sequencing
|
WO2022115506A2
(en)
|
2020-11-24 |
2022-06-02 |
University Of Houston System |
Salicylic acid-inducible gene expression compositions and systems for cells
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
EP4256052A1
(en)
|
2020-12-02 |
2023-10-11 |
Decibel Therapeutics, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
CA3201767A1
(en)
|
2020-12-14 |
2022-06-23 |
Thomas M. Schmitt |
Compositions and methods for cellular immunotherapy
|
KR20230124682A
(ko)
|
2020-12-23 |
2023-08-25 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
Rna를 봉입하는 아넬로바이러스 캡시드의 시험관 내어셈블리
|
WO2022147133A1
(en)
|
2020-12-30 |
2022-07-07 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
CN116724109A
(zh)
|
2020-12-31 |
2023-09-08 |
Vor生物制药股份有限公司 |
用于cd34基因修饰的组合物和方法
|
EP4271795A1
(en)
|
2020-12-31 |
2023-11-08 |
CRISPR Therapeutics AG |
Universal donor cells
|
EP4271802A1
(en)
*
|
2021-01-04 |
2023-11-08 |
Inscripta, Inc. |
Mad nucleases
|
JP2024501757A
(ja)
|
2021-01-05 |
2024-01-15 |
ホライズン・ディスカバリー・リミテッド |
遺伝子組換え細胞の製造方法
|
US11332742B1
(en)
|
2021-01-07 |
2022-05-17 |
Inscripta, Inc. |
Mad nucleases
|
CA3207102A1
(en)
|
2021-01-12 |
2022-07-21 |
March Therapeutics, Inc. |
Context-dependent, double-stranded dna-specific deaminases and uses thereof
|
AU2022215636A1
(en)
*
|
2021-02-08 |
2023-09-21 |
Emendobio Inc. |
Omni 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 crispr nucleases
|
CA3207958A1
(en)
|
2021-02-16 |
2022-08-25 |
Julyun OH |
Compositions and methods for treating her2 positive cancers
|
US11884924B2
(en)
|
2021-02-16 |
2024-01-30 |
Inscripta, Inc. |
Dual strand nucleic acid-guided nickase editing
|
US20240052372A1
(en)
|
2021-02-25 |
2024-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Allele-specific genome editing of the nr2e3 mutation g56r
|
WO2022187125A1
(en)
*
|
2021-03-01 |
2022-09-09 |
The Regents Of The University Of California |
Methods for generating a crispr array
|
GB202103131D0
(en)
|
2021-03-05 |
2021-04-21 |
Biosystems Tech Limited |
Method for preparation of research organisms
|
WO2022194908A1
(en)
|
2021-03-17 |
2022-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
EP4314266A1
(en)
|
2021-03-22 |
2024-02-07 |
Lifeedit Therapeutics, Inc. |
Dna modifyng enzymes and active fragments and variants thereof and methods of use
|
WO2022214632A1
(en)
|
2021-04-07 |
2022-10-13 |
Neoplants Sas |
Compositions and methods for indoor air remediation
|
EP4320234A2
(en)
|
2021-04-07 |
2024-02-14 |
Astrazeneca AB |
Compositions and methods for site-specific modification
|
WO2022217086A1
(en)
|
2021-04-09 |
2022-10-13 |
Vor Biopharma Inc. |
Photocleavable guide rnas and methods of use thereof
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
WO2022219175A1
(en)
|
2021-04-15 |
2022-10-20 |
Keygene N.V. |
Mobile endonucleases for heritable mutations
|
BR112023021051A2
(pt)
|
2021-04-15 |
2023-12-26 |
Keygene Nv |
Plantas recalcitrantes de corregeneração
|
WO2022221699A1
(en)
|
2021-04-16 |
2022-10-20 |
Beam Therapeutics, Inc. |
Genetic modification of hepatocytes
|
EP4326873A1
(en)
|
2021-04-22 |
2024-02-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
EP4326903A1
(en)
|
2021-04-23 |
2024-02-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
EP4337769A1
(en)
|
2021-05-10 |
2024-03-20 |
SQZ Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
EP4347805A1
(en)
|
2021-05-27 |
2024-04-10 |
Astrazeneca AB |
Cas9 effector proteins with enhanced stability
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
IL308806A
(en)
|
2021-06-01 |
2024-01-01 |
Arbor Biotechnologies Inc |
Gene editing systems including nuclease crisper and their uses
|
EP4347830A2
(en)
|
2021-06-02 |
2024-04-10 |
Beam Therapeutics Inc. |
Circular guide rnas for crispr/cas editing systems
|
WO2022256437A1
(en)
|
2021-06-02 |
2022-12-08 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
EP4352226A1
(en)
|
2021-06-07 |
2024-04-17 |
Yale University |
Peptide nucleic acids for spatiotemporal control of crispr-cas binding
|
WO2022261394A1
(en)
|
2021-06-11 |
2022-12-15 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
GB202108585D0
(en)
|
2021-06-16 |
2021-07-28 |
Rockend Ltd |
Methods and compositions
|
CA3223311A1
(en)
|
2021-06-18 |
2022-12-22 |
Andrea BARGHETTI |
Compositions and methods for targeting, editing or modifying human genes
|
WO2022272293A1
(en)
*
|
2021-06-23 |
2022-12-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for efficient retron production and genetic editing
|
US20230016422A1
(en)
|
2021-06-23 |
2023-01-19 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
WO2023283585A2
(en)
|
2021-07-06 |
2023-01-12 |
Vor Biopharma Inc. |
Inhibitor oligonucleotides and methods of use thereof
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
WO2023283495A1
(en)
*
|
2021-07-09 |
2023-01-12 |
The Brigham And Women's Hospital, Inc. |
Crispr-based protein barcoding and surface assembly
|
TW202317602A
(zh)
|
2021-07-15 |
2023-05-01 |
福瑞德哈金森腫瘤中心 |
嵌合多肽
|
CA3226664A1
(en)
|
2021-07-23 |
2023-01-26 |
Brian CAFFERTY |
Guide rnas for crispr/cas editing systems
|
CA3227105A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
AU2022324093A1
(en)
|
2021-08-02 |
2024-02-08 |
Vor Biopharma Inc. |
Compositions and methods for gene modification
|
KR102573948B1
(ko)
|
2021-08-09 |
2023-09-01 |
경상국립대학교산학협력단 |
Mips1과 이의 상동체 동시 타겟 유전자교정 시스템 및 이의 용도
|
KR102573952B1
(ko)
|
2021-08-09 |
2023-09-01 |
경상국립대학교산학협력단 |
E2와 이의 상동체 동시 타겟 유전자교정 시스템 및 이의 용도
|
KR102573947B1
(ko)
|
2021-08-09 |
2023-09-01 |
경상국립대학교산학협력단 |
콩 유전자교정 효율 증대를 위한 유전자교정 시스템 및 이의 용도
|
KR102574819B1
(ko)
|
2021-08-09 |
2023-09-04 |
경상국립대학교산학협력단 |
P34와 이의 상동체 동시 타겟 유전자교정 시스템 및 이의 용도
|
KR102584891B1
(ko)
|
2021-08-09 |
2023-10-04 |
경상국립대학교산학협력단 |
GmIPK1 유전자교정 시스템 및 이의 용도
|
EP4144841A1
(en)
*
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
|
US11884915B2
(en)
|
2021-09-10 |
2024-01-30 |
Agilent Technologies, Inc. |
Guide RNAs with chemical modification for prime editing
|
WO2023049742A2
(en)
*
|
2021-09-21 |
2023-03-30 |
Scribe Therapeutics Inc. |
Engineered casx repressor systems
|
WO2023049926A2
(en)
|
2021-09-27 |
2023-03-30 |
Vor Biopharma Inc. |
Fusion polypeptides for genetic editing and methods of use thereof
|
WO2023052366A1
(en)
|
2021-09-28 |
2023-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of beta-hemoglobinopathies
|
CA3233097A1
(en)
|
2021-09-30 |
2023-04-06 |
Katherine Diane GRIBBLE |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
KR20230051095A
(ko)
|
2021-10-06 |
2023-04-17 |
주식회사 진코어 |
유전자 편집을 위한 TaRGET 시스템 및 이의 용도
|
WO2023064924A1
(en)
|
2021-10-14 |
2023-04-20 |
Codiak Biosciences, Inc. |
Modified producer cells for extracellular vesicle production
|
WO2023064732A1
(en)
|
2021-10-15 |
2023-04-20 |
Georgia State University Research Foundation, Inc. |
Delivery of therapeutic recombinant uricase using nanoparticles
|
WO2023070043A1
(en)
|
2021-10-20 |
2023-04-27 |
Yale University |
Compositions and methods for targeted editing and evolution of repetitive genetic elements
|
CA3234809A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
|
WO2023076944A1
(en)
|
2021-10-26 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Overexpression of lemd2, lemd3, or chmp7 as a therapeutic modality for tauopathy
|
AU2022379633A1
(en)
|
2021-10-27 |
2024-04-11 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for expressing factor ix for hemophilia b therapy
|
WO2023077053A2
(en)
|
2021-10-28 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
CA3231899A1
(en)
|
2021-11-04 |
2023-05-11 |
Trevor Stitt |
Non-human animals comprising a modified cacng1 locus
|
WO2023086422A1
(en)
|
2021-11-09 |
2023-05-19 |
Vor Biopharma Inc. |
Compositions and methods for erm2 modification
|
GB202117314D0
(en)
|
2021-11-30 |
2022-01-12 |
Clarke David John |
Cyclic nucleic acid fragmentation
|
WO2023099591A1
(en)
|
2021-12-01 |
2023-06-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
US20230193310A1
(en)
|
2021-12-10 |
2023-06-22 |
Seminis Vegetabe Seeds, Inc. |
Lettuce plants having resistance to downy mildew
|
GB202118058D0
(en)
|
2021-12-14 |
2022-01-26 |
Univ Warwick |
Methods to increase yields in crops
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023111173A1
(en)
|
2021-12-16 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An ezh2 degrader or inhibitor for use in the treatment of resistant acute myeloid leukemia
|
WO2023111225A1
(en)
|
2021-12-17 |
2023-06-22 |
Keygene N.V. |
Double decapitation of plants
|
WO2023122506A1
(en)
|
2021-12-20 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
WO2023119135A1
(en)
|
2021-12-21 |
2023-06-29 |
Benson Hill, Inc. |
Compositions and methods for modifying genomes
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023122800A1
(en)
|
2021-12-23 |
2023-06-29 |
University Of Massachusetts |
Therapeutic treatment for fragile x-associated disorder
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023139557A1
(en)
|
2022-01-24 |
2023-07-27 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2023144104A1
(en)
|
2022-01-25 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of βeta-thalassemia
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150620A1
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Crispr-mediated transgene insertion in neonatal cells
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
EP4223877A1
(en)
*
|
2022-02-08 |
2023-08-09 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
System and method for editing genomic dna to modulate splicing
|
US20230257432A1
(en)
|
2022-02-11 |
2023-08-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for screening 4r tau targeting agents
|
WO2023152351A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstream of meg3 in the dlk1/dio3 locus
|
WO2023159103A1
(en)
|
2022-02-17 |
2023-08-24 |
The Board Of Regents Of The University Of Texas System |
CRISPR/SpCas9 VARIANT AND METHODS FOR ENHANCED CORRECTON OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS
|
WO2023156587A1
(en)
|
2022-02-18 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
US20230265421A1
(en)
*
|
2022-02-21 |
2023-08-24 |
Zhuhai Shu Tong Medical Technology Co., Ltd. |
Type ii crispr/cas9 genome editing system and the application thereof
|
WO2023164670A2
(en)
*
|
2022-02-25 |
2023-08-31 |
Duke University |
Crispr-cas9 compositions and methods with a novel cas9 protein for genome editing and gene regulation
|
WO2023164636A1
(en)
|
2022-02-25 |
2023-08-31 |
Vor Biopharma Inc. |
Compositions and methods for homology-directed repair gene modification
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
WO2023192872A1
(en)
|
2022-03-28 |
2023-10-05 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
WO2023196816A1
(en)
|
2022-04-04 |
2023-10-12 |
Vor Biopharma Inc. |
Compositions and methods for mediating epitope engineering
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
CN114864002B
(zh)
*
|
2022-04-28 |
2023-03-10 |
广西科学院 |
一种基于深度学习的转录因子结合位点识别方法
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
WO2023213831A1
(en)
|
2022-05-02 |
2023-11-09 |
Fondazione Telethon Ets |
Homology independent targeted integration for gene editing
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023217888A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from βeta-thalassemia
|
WO2023219657A1
(en)
*
|
2022-05-13 |
2023-11-16 |
Sri International |
Programmable recruitment of transcription factors to endogenous genes
|
WO2023225665A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023225410A2
(en)
|
2022-05-20 |
2023-11-23 |
Artisan Development Labs, Inc. |
Systems and methods for assessing risk of genome editing events
|
WO2023230549A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulation of tumor suppressors and oncogenes
|
WO2023230570A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating genetic drivers
|
WO2023230578A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating circulating factors
|
WO2023230573A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulation of immune responses
|
WO2023230566A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating cytokines
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
WO2023235677A1
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
WO2023233339A1
(en)
|
2022-06-01 |
2023-12-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
WO2023233342A2
(en)
|
2022-06-01 |
2023-12-07 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
US20230404003A1
(en)
|
2022-06-21 |
2023-12-21 |
Seminis Vegetable Seeds, Inc. |
Novel qtls conferring resistance to cucumber mosaic virus
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
EP4299739A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
WO2024006802A1
(en)
|
2022-06-30 |
2024-01-04 |
Pioneer Hi-Bred International, Inc. |
Artificial intelligence-mediated methods and systems for genome editing
|
WO2024005864A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
WO2024005863A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
EP4299733A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
GB2621813A
(en)
|
2022-06-30 |
2024-02-28 |
Univ Newcastle |
Preventing disease recurrence in Mitochondrial replacement therapy
|
JP7152094B1
(ja)
*
|
2022-06-30 |
2022-10-12 |
リージョナルフィッシュ株式会社 |
tracrRNAユニット、及びゲノム編集方法
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024015925A2
(en)
|
2022-07-13 |
2024-01-18 |
Vor Biopharma Inc. |
Compositions and methods for artificial protospacer adjacent motif (pam) generation
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024018056A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
WO2024020597A1
(en)
|
2022-07-22 |
2024-01-25 |
The Johns Hopkins University |
Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
|
WO2024026313A1
(en)
|
2022-07-25 |
2024-02-01 |
The Regents Of The University Of California |
Methods of producing and using avian embryonic stem cells and avian telencephalic organoids
|
WO2024023734A1
(en)
|
2022-07-26 |
2024-02-01 |
Bit Bio Limited |
MULTI-gRNA GENOME EDITING
|
WO2024026488A2
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a modified transferrin receptor locus
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
WO2024036190A2
(en)
|
2022-08-09 |
2024-02-15 |
Pioneer Hi-Bred International, Inc. |
Guide polynucleotide multiplexing
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
US20240067968A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024042489A1
(en)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024042168A1
(en)
|
2022-08-26 |
2024-02-29 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
|
WO2024042165A2
(en)
|
2022-08-26 |
2024-02-29 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
WO2024052318A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
WO2024056659A1
(en)
|
2022-09-13 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Method for treating prostate cancer and other epithelial cancers
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
WO2024073679A1
(en)
|
2022-09-29 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
WO2024073751A1
(en)
|
2022-09-29 |
2024-04-04 |
Vor Biopharma Inc. |
Methods and compositions for gene modification and enrichment
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
CN115678903B
(zh)
*
|
2022-11-03 |
2024-04-02 |
贵州大学 |
一种白背飞虱Ago1基因、合成dsRNA的方法及其应用
|